  
 
 
 
 
 
 
 
Document type:  Amended  Protocol Version  
EUDRACT number:  2020 -003959 -16 
Version number:  01  (Amended Protocol Clean ) 
Clinical Trial Phase:  III 
Release date:  20-Dec-2021 (content final)  
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
 
 
 Nov
artis Research and Development
AAA405
             Clinical Trial Protocol CAAA405A12301/ [STUDY_ID_REMOVED]
  Phase III study for evaluation of the diagnostic  
performance of [18F]CTT1057 PET imaging in patients with
  prostate cancer with rising PSA levels [biochemical
  recurrence (BCR)] (GuidePath)
[COMPANY_001]  Confidential  Page 2 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Table of contents  
Table of contents ................................................................................................................. [ADDRESS_30116] of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Protocol Amendment 01 (20- Dec-2021) ........................................................................... 13 
Protocol Summary  ............................................................................................................. 21 
1 Introduction ....................................................................................................................... 25 
1.1 Background ............................................................................................................ 25 
1.2 Purpose .................................................................................................................. 28 
2 Objectives and endpoints ................................................................................................... 28 
2.1 Primary estimands  ................................................................................................. 31 
2.2 Secondary estimands ............................................................................................. 33 
3 Study design ...................................................................................................................... 33 
4 Rationale ............................................................................................................................ 36 
4.1 Rationale for study design ..................................................................................... 36 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 39 
4.3 Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 39 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 39 
4.5 Risks and benefits .................................................................................................. 39 
4.6 Rationale for Public Health Emergency mitigation procedures  ............................ 40 
5 Study Population ............................................................................................................... 40 
5.1 Inclusion criteria  .................................................................................................... 41 
5.2 Exclusion criteria  ................................................................................................... 41 
6 Treatment  ........................................................................................................................... 42 
6.1 Study treatment ...................................................................................................... 42 
6.1.1 Investigational and control drugs .......................................................... 42 
6.1.2 Additional study treatments .................................................................. 43 
6.1.3 Supply of study treatment ..................................................................... 43 
6.1.4 Treatment arms/group  ........................................................................... 44 
[COMPANY_001]  Confidential  Page 3 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 6.1.5 Treatment duration  ................................................................................ 44 
6.2 Other treatment(s)  .................................................................................................. 44 
6.2.1 Concomitant therapy  ............................................................................. 44 
6.2.2 Prohibited medication  ........................................................................... 45 
6.3 Participant numbering, treatment assignment, randomization  .............................. 45 
6.3.1 Participant numbering  ........................................................................... 45 
6.3.2 Treatment assignment , randomization .................................................. 45 
6.4 Treatment blinding  ................................................................................................ 46 
6.5 Dose escalation and dose  modification .................................................................. 46 
6.5.1 Follow-up for toxicities ......................................................................... 46 
6.6 Additional treatment guidance ............................................................................... 46 
6.6.1 Treatment compliance  ........................................................................... 46 
6.7 Prepar ation and dispensation  ................................................................................. 47 
6.7.1 Handling of study treatment and additional treatment .......................... 47 
6.7.2 Instruction for preparing and administering study treatment  ................ 49 
7 Informed consent procedures ................................................................................. 50 
8 Visit schedule and assessments  ............................................................................. 51 
8.1 Screening  ............................................................................................................... 59 
8.1.1 Eligibility screening  .............................................................................. 59 
8.1.2 Information to be collected on screening failures ................................. 59 
8.2 Participant demographics/other baseline characteristics  ....................................... 59 
8.3 Efficacy  .................................................................................................................. 60 
8.3.1 Imaging for tumor assessment  .............................................................. 60 
8.3.2 Histopathology assessments  .................................................................. 64 
8.3.3 PSA level assessments  .......................................................................... 64 
8.3.4 Appropriateness of efficacy assessments  .............................................. 64 
8.4 Safety  ..................................................................................................................... 64 
8.4.1 Laboratory evaluations  .......................................................................... 66 
8.4.2 Electrocardiogram (ECG) ..................................................................... 68 
8.4.3 Pregnancy and contraception ................................................................ 68 
8.4.4 Appropriateness of safety measurements  .............................................. 68 
8.5 Additional assessments  .......................................................................................... 68 
[COMPANY_001]  Confidential  Page 4 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 8.5.[ADDRESS_30117] to follow -up ................................................................................... 70 
9.2 Withdrawal of informed consent/Opposition to use data/biological samples  ....... [ADDRESS_30118]- study treatment  .......................................................... 71 
10 Safety monitoring and reporting  ............................................................................ 72 
10.1 Definition of adverse events and reporting requirements ...................................... 72 
10.1.1 Adverse events ...................................................................................... 72 
10.1.2 Serious adverse events  .......................................................................... 73 
10.1.3 SAE reporting........................................................................................ 74 
10.1.4 Pregnancy reporting .............................................................................. 75 
10.1.5 Reporting of study treatment errors including misuse .......................... 75 
10.2 Additional Safety Monitoring  ................................................................................ 76 
10.2.1 Steering Committee  ............................................................................... 76 
11 Data Collection and Database management  .......................................................... 76 
11.1 Data collection  ....................................................................................................... 76 
11.2 Database management and quality control ............................................................ 76 
11.3 Site monitoring  ...................................................................................................... 77 
12 Data analysis and statistical methods  .................................................................... 77 
12.1 Analysis sets .......................................................................................................... 77 
12.2 Participant demographics and other baseline characteristics  ................................. 78 
12.3 Treatments  ............................................................................................................. 78 
12.4 Analysis of the primary endpoint(s)/estimand(s) .................................................. 78 
12.4.1 Definition of primary endpoint(s)/estimand(s)  ..................................... 78 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 79 
12.4.3 Handling of remaining intercurrent events of primary estimand  .......... 79 
12.4.4 Handling of missing values not related to intercurrent event  ............... 79 
12.4.5 Sensitivity analyses for primary endpoint/estimand  ............................. 79 
[COMPANY_001]  Confidential  Page 5 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 12.4.6 Supplementary analysis ......................................................................... 79 
12.5 Analysis of secondary endpoints/estimands  .......................................................... 80 
12.5.1 Efficacy and/or Pharmac odynamic endpoint(s)  .................................... 80 
12.5.2 Safety endpoints .................................................................................... 82 
  84 
12.7 Interim analyses  ..................................................................................................... 84 
12.8 Sample size calculation .......................................................................................... 84 
12.8.1 Primary endpoint(s)  ............................................................................... 85 
13 Ethical considerations an d administrative procedures  ........................................... 86 
13.1 Regulatory and ethical compliance ........................................................................ 86 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 86 
13.3 Publication of study protocol and results............................................................... 87 
13.4 Quality Control and Quality Assurance  ................................................................. 87 
14 Protocol adherence ................................................................................................. 87 
14.1 Protocol amendments ............................................................................................. 88 
15 References .............................................................................................................. 89 
16 Appendices ............................................................................................................ 95 
16.1 Appendix 1: Common Terminology Criteria for Adverse Events......................... 95 
16.2 Appendix 2: Response Evaluation Criteria in Solid Tumors................................. 96 
16.3 Appendix 3: PCWG3 ............................................................................................. 97 
16.4 Appendix 4: Patient Management questionnaire ................................................... [ADDRESS_30119] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 28 
Table 6-1 Investigational PET imaging agents ...................................................... 42 
Table 8 -1 Assessment Schedule  ............................................................................ 52 
Table 8 -2 Imaging Assessment Collection Plan  .................................................... 61 
Table 8 -3 Assessments and Specifications  ............................................................ 66 
Table 8 -4 Performance Status ................................................................................ 66 
Table 8 -5 Laboratory a ssessments  ......................................................................... 67 
Table 10-1 Guidance for capturing the study treatment errors including misuse  ... 75 

[COMPANY_001]  Confidential  Page 6 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 List of figures  
Figure 3-1 Study Design ......................................................................................... 34 
 
[COMPANY_001]  Confidential  Page 7 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 List of abbreviations  
ADT Androgen Deprivation Therapy  
AE Adverse Event  
ALT Alanine Aminotransferase  
ASCT2  Alanine, Serine, Cysteine Transporter [ADDRESS_30120] localization rate   
CMO&PS  Chief Medical Office and Patient Safety  
CO Country Organization  
COVID -19 Coronavirus disease 2019  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract Research Organization  
CT Computerized Tomography  
CTC Common Toxicity Criteria  
CTCAE  Common Terminology Criteria for Adverse Events  
cTNM  Clinical Stage  
CTS Composite Truth Standard  
DBP Diastolic Blood Pressure  
EANM  European Association of Nuclear Medicine  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic  Case Report/Record Form  
ED Effective Dose  
EDC  Electronic Data Capture  
EFF Efficacy Analysis Set  
EMA  European Medicines Agency   
EOS  Study completion  
EOT End of Treatment  
ePLND  extended Pelvic Lymph Node Dissection  
eSAE  electronic Serious Adverse Event  
EU European Union  
F-SAF [18F]CTT1057 Safety Set  
[COMPANY_001]  Confidential  Page 8 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 FAS Full Analysis Set  
FDG  Fluorodeoxyglucose  
FN False Negative  
FP False Positive  
Ga-SAF [68Ga]Ga -PSMA -11 Safety Set  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transferase  
GMP  Good Manufacturing Practice  
HR Heart Rate   
i.v. intravenous  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
IMP Investigational Medicinal Product  
IN Investigator Notification  
IRB Institutional Review Board  
IRT Interactive Response Technology  
LAT-1 L-Type Amino Acid Transporter 1  
LDH lactate dehydrogenase  
LHRH  Luteinizing Hormone -Releasing Hormone  
MBq Mega -Becquerel  
MCH  Mean Corpuscular Hemoglobin  
mCi Millicurie  
mCRPC  metastatic -Castration Resistant Prostate Cancer  
MedDRA  Medical dictionary for regulatory activities  
mg milligram(s)  
min minute(s)  
mL milliliter(s)  
MRI Magnetic Resonance Imaging  
mSV  millisievert  
NCI National Cancer Institute  
p.i. post-injection  
PCa Prostate Cancer  
PCWG3  Prostate Cancer Working Group [ADDRESS_30121] Pelvic Lymph Node  
PPV Positive Predictive Value  
PSA Prostate Specific Antigen  
PSMA  Prostate Specific Membrane Antigen  
[COMPANY_001]  Confidential  Page 9 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 pTNM  pathological stage  
QC Quality Control  
QMS  Quality Management System  
RECIST  Response Evaluation Criteria In Solid Tumors  
RP Radical Prostatectomy   
RR Respi[INVESTIGATOR_30745] 10 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Glossary of terms  
Additional treatment  Medicinal products that may be used during the clinical trial as described in 
the protocol, but not as an investigational medicinal product (e.g. any 
background therapy)  
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study participant  
Clinical Tria l Team  A group of people responsible for the planning, execution and reporting of all clinical trial activities. Examples of team members include the Study 
Lead, Medical Monitor, Trial Statistician etc.  
Coded Data  Personal Data which has been de -identifi ed by [CONTACT_30760] a code.  
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 
mg once a day, 75 mg twice a day)  
Discontinuation from 
study  
 Point/time when the participant permanently stops receiving the study 
treatment and further protocol required assessments or follow -up, for any 
reason. No specific request is made to stop the use of their samples or 
data.  
Discontinuation from 
study  treatment  Point/time when the participant permanently stops receiving the study treatment for any reason (prior to the planned completion of study drug 
administration, if any). Participant agrees to the other protocol required assessments including follow- up. No specific request is  made to stop the 
use of their samples or data.  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web -based applications, 
interactive voice response syst ems and clinical laboratory interfaces. EDC 
includes the use of electronic Case Report Forms (eCRFs) which are used 
to capture data transcribed from source data/documents  used at the point 
of care  
End of the clinical trial  The end of the clinical trial is defined as the last visit of the last participant 
or at a later point in time as defined by [CONTACT_30761]/time of participant entry into the study at which informed consent 
must be obtained.  The action of enrolling one or more participants . 
Estimand   As defined in the ICH E9(R1) addendum, estimand is a precise description of the treatment effect reflecting the clinical question posed by [CONTACT_30762]. It summarizes at a population- level what the outcomes would be 
in the same participants under different treatment conditions being compared. Attributes of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the remaining intercurrent events are addressed and a population- level 
summary for the variable.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or the existence of the measurements associated with the 
clinical question of interest.  
Investigational drug/ 
treatment  The drug whose properties are being tested in the study  
Medication number  A unique identifier on the label of medication kits  
[COMPANY_001]  Confidential  Page 11 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study  
Other treatment  Treatment that may be needed/allowed during the conduct of the study 
(i.e. concomitant or rescue therapy)  
Participant  A trial participant (can be a healthy volunteer or a patient)"Subject" is used 
in data collection  
Participant number  A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant 
and should be used to identify the participant throughout the study for all 
data collected, sample labels, etc.  
Period  The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and 
will be used in clinical trial database setup and eventually in analysis  
Perpetrator drug  A drug which affects the pharmacokinetics of the other drug  
Personal data Participant information collected by [CONTACT_6554]. This data 
includes participant identifier information, study information and biological 
samples.  
Premature participant withdrawal  Point/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this 
time all study drug administration is discontinued and no further 
assessments are planned  
Randomization  The process of assigning trial participants to investigational drug or 
control/comparator drug using an element of chance to determine the 
assignments in order to reduce bias.  
Randomization 
number  A unique identifier assigned to each randomized parti cipant  
Re-screening  If a participant fails the initial screening and is considered as a Screen 
Failure, he can be invited once for a new Screening visit after medical 
judgment and as specified by [CONTACT_30763] a location that is not the 
investigative site where the investigator will conduct the trial, but is for 
example a home or another appropriate location  
Screen Failure A participant who did not meet one or more criteria that were required for 
participation in the study  
Source Data/Document  Source data refers to the initial record, document, or primary location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper   
Stage in cancer  The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer 
has spread from the original site to other parts of the body  
Start of the clinical 
trial The start of the clinical trial is defined as the signature [CONTACT_30832] [CONTACT_30764]; inclu des 
investigational drug(s), control(s) or background therapy . 
[COMPANY_001]  Confidential  Page 12 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Treatment arm/group  A treatment arm/group defines the dose and regimen or the combination, 
and may consist of [ADDRESS_30122], which might or might not 
be the same as the study treatment.  
Variable (or endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address the clinical question.  The specification of the variable 
might include whether the participant experiences an intercurrent event.  
Withdrawal of study 
consent (WoC)/ 
Opposition to use of  
data /biological  
samples  Withdrawal of consent from the study occurs  when the participant explicitly requests to stop use of their data and biological samples  
(opposition to use data and biological samples) AND no longer wishes to 
receive study treatment, AND does not want agree to  further   protocol 
required assessments. This request should be in writing (depending on 
local regulations) and recorded in the source documentation.  
Opposition to use data/biological samples occurs in the countries where 
collection and processing of personal data is justified by a different legal 
reason than consent.  
[COMPANY_001]  Confidential  Page 13 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Protocol Amendment 01 (20-Dec-2021)  
Amendment Rationale  
As of the date of release of this protocol amendment, [ADDRESS_30123] been randomized in the study 
(12 dosed).  
The main purpose of the amendment is to clarify the inclusion criterion on PSA level requirements for 
confirmation of biochemical recurrence (BCR) following radiation therapy and following Radical 
Prostatectomy (RP) to avoid misinterpretation and ensure full alignment with the published definitions 
for BCR per AUA and ASTRO -Phoenix guidelines and with the targeted study population (patients who 
have BCR following initial definitive therapy). The amendment also clarifies that subjects with prior salvage radiation therapy or salvage surgery are not eligible for the study to ensure alignment with the targeted patient population. Other clarifications and corrections of discrepancies or errors have been 
implemented across the protocol. All changes implemented are detailed below with their justification.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes herein do not affect the Informed Consent. 
 
Main changes implemented in the protocol amendment  
Section  Change  Description and rationale  
Protocol summary  
Section 2.1 
Section 3 
Section 5  Targeted population in 
the study  
Additional information 
provided. Clarification that targeted population for 
the study is prostate cancer patients 
diagnosed with biochemical recurrence (BCR) after initial definitive therapy (with 
either RP or curative intent RT)  
Section 3 Clarification of safety assessments follow -up 
timing  Updated to ensure that safety assessments to be performed at the safety follow-up at 14 days (+ 3 day  window) after each 
PET/CT scan day are also performed before any surgery/radiation therapy/initiation of antineoplastic medication, in the event where the patient would undergo surgery, radiation therapy or initiating any antineoplastic medication (provided all CTS procedures have been completed before this initiation) prior to 
planned s afety visit.  
Protocol summary  
Section 5.1  Update of Inclusion criterion #[ADDRESS_30124] be 
confirmed by [CONTACT_30765] ≥0.2 
ng/mL measured at least Modified inclusion criterion (numbered 3a) to clarify the requirements fo r biochemical 
recurrence (BCR) following initial definitive therapy with either R P or 
curative-intent radiation therapy (RT) and fully align with the definitions of BCR from the publications referred to for AUA 
[COMPANY_001]  Confidential  Page 14 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 6 weeks after RP with a 
second confirmatory 
persistent PSA level of >0.2 ng/mL. For patients who had prior curative- intent radiation 
therapy (RT), BCR is defined as a rise of serum PSA measurement of 2 or more ng/mL above the nadir PSA observed post 
RT. and ASTRO -Phoenix criteria and the 
targeted p opulation. 
Protocol summary  
Section 5.2  
Section 6.2.2 Removal of exclusion 
criterion #6 and update of exclusion criterion #7 and clarification that LHRH analogues include LRHR agonists or antagonists  Exclusion criterion #6 is removed as this is 
not relevant for the purpose of this study to 
completely exclude prior treatment with LHRH analogues ( agonists or antagonists) 
which are part of ADT. Many subjects receive ADT (including LHRH analogues) in combination with primary curative intent radiation the rapy. The same washout 
period as for other ADTs (9 months) should apply for LHRH analogues. 
Exclusion criterion #7 was updated  
accordingly (numbered 7a) to exclude any 
prior ADT including LHRH analogues (agonists or antagonists) within 9 months before scre ening. 
Section 6.2.2 was also updated to clarify 
that LHRH analogues include LHRH 
agonists or antagonists.  
Protocol summary  
Section 5.2  Addition of a new 
exclusion criteria (#12)  
 
 Clarification that patients who received 
prior salvage surgery or salvage RT are not 
eligible for the study as the targeted population is patients with BCR following 
initial definitive therapy.   
Protocol summary  
Table 2 -1Section 
12.6 Update of Secondary endpoint and Clarification that the secondary endpoint (based on central imaging reads) and 
for concordance between 
[
18F]CTT1057 and [68Ga]Ga -PSMA -11 for 
detection of PSMA -positive lesions (in 
terms of number of lesions detected and 

[COMPANY_001]  Confidential  Page 15 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 their location) w ill be assessed at lesion 
level, not patient level.   
Protocol summary  
Section [ADDRESS_30125] both an 
evaluable [
18F]CTT1057 PET/CT 
scan imaging,  and at least one evaluable 
CTS assessment and have not received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and 
CTS procedures.   
Section 3 
Section 4.1 
Section 8.3.1 
 Clarification on 
[68Ga]Ga -PSMA -11 
PET/CT scan 
acquisition 
requirements  Clarification that [68Ga]Ga -PSMA -11 
PET/CT scan is mandatory for all patients randomized. 
Section [ADDRESS_30126] be acquired within the 8 weeks either prior to or 
following the [18F]CTT10 57 PET/CT scan.  
Section 8.3.1  Addition of Table 8 -2 Addition to provide clarity to sites on the 
imaging procedures expected for this study and their timing. Subsequent tables in the 
document were re -numbered accordingly.   
Section 8.3.1 
  
 
  
Section 8.3.1  Clarification on 
Characteristics of lesions  Clarification that the characteristics of 
lesions should be documented for lesions 
that are visually positive on the [68Ga]Ga -
PSMA -11 PET but not considered as 
prostate cancer (i.e.  non prostate cancer 
tumoral lesions, or benign non tumoral 
lesions).  
Section 3 
Section 12.5.1 
Section 16.4 
(Appendix 4)  Addition of a new option in questionnaire #2 Addition of a new option named “Radiation alone with change in radiation treatment plan”, which will be applicable only for questionnaire 2, in order to capture 
any intended change in the radiation plan 

[COMPANY_001]  Confidential  Page 16 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 (e.g. change in the extent of the field of 
radiations ).  
Section 6.2.1 Clarification of use of 
diuretics  Clarification that the use of diuretics (e.g. furosemide) to help subject to void before PET/CT scan imaging acquisition is allowed in case of need, upon the 
discretion of the investigator.  
Section 6.2 .2 Clarification of use of 
LHRH analogues and anti- androgens  Clarification  that use of any ADT 
including LHRH analogues (agonists or antagonists) as well as anti -androgens 
(both first and second generation compounds) and 5- alpha reductase 
inhibitors is prohibited prior to completing both PET imaging scans and CTS procedures, to ensure that the same lesions 
are assessed on PET/CT scans and CTS procedures without potential reduction in lesion size and therefore detectability due to administration of antineoplastic 
medications.  
Section 8.5.1 Clarification of patient management ques tionnaire #2  
Timing for completion  Clarification that patient management questionnaire 2 should be completed before [
68Ga]Ga -PSMA -11 PET/CT is performed 
for subjects assigned to sequence 1.  
Section 10.1.[ADDRESS_30127] dose of study 
treatment (instead of last study visit) for alignment with the definition of on -
treatment period provided in Section 
12.5.2.  
Other changes implemented in protocol amendment:  
Section  Change  Description and rationale  
Table of Contents 
List of tables  
List of figures  Updates  Modified to reflect changes made in 
protocol body 
Glossary of terms  Updates and 
clarification  Addition of definitions and clarifications of 
some definitions.  
Table 2 -1 Incidence of AEs wording clarification Updated to remove that incidence of AEs 
will be described after each PET tracer 
injection, after each PET/CT scans and at 
24-72 h after each PET/CT scan. Indeed, 
the incidence of AEs will be  summarized 
[COMPANY_001]  Confidential  Page 17 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 for AEs occurring during each treatment 
period (i.e. within 14 days after each PET 
tracer administration) as described in 
Section 12.5.[ADDRESS_30128] S levels 
will be applied hierarchically at lesion 
level for efficacy analyses. CTS level 2 will be used as SoT if histopathology is not available for a lesion, inconclusive (if biopsy/surgery tissue sample is not evaluable for histopathology assessment due to sample quality or inadequate quantity or any other technical causes) or negative (for biopsy only). CTS level 3 will be used as SoT if CTS level 2 imaging diagnostic procedures are not available or inconclusive (i.e. if images are not interpretable due  to poor or inadequate 
image quality that precludes reliable assessment). Section 4.1 also clarified that for CTS level 3, the lesion on the [
18F]CTT1057 PET/CT scan that was 
irradiated will be classified as a true positive (TP) in case of ≥50% PSA decrease 3 months after RT, or as FP 
otherwise.  
Section 4.1 
Section 12.5.1 
Section 12.8.1 
 Regions definition for 
region- level efficacy 
endpoints analysis  Updated to clearly mention the different 
regions considered for this study as used for the region -level efficacy endpoints 
analyses: prostate region (comprising prostate bed/prostate gland and any local invasion of the urinary bladder, rectum or seminal vesicles), pelvic lymph nodes (PLN) region, extra -PLN region, skeletal 
region and visceral re gion).  
[COMPANY_001]  Confidential  Page 18 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Section 6.3.[ADDRESS_30129] RT as part 
of additional follow-up if CTS level 3 is applicable for the patient, as described in 
Section 8.3.3.  
Table 8 -1 (footnote*)  Addition of footnote*  Addition of footnote* to clarify that all screening assessments to confirm eligibility must be done prior 
randomization.  
Table [ADDRESS_30130]’s eligibility. Day 1 (first dosing visit) should occur maximum 14 days after enrolment. 
Table 8 -1 (footnote 
7) Update on ordering 
requirements  Updated to mention that ordering should be 
done after randomization and based on the 
radiopharmaceutical that requ ires the 
longest period from order to delivery  
Table 8 -1 Update of Day 1 visit window  The table is updated to allow a visit window of 7 days since the enrolment/randomization could occur 
earlier than [ADDRESS_30131] results (that are part of baseline characterictics data) will be 
assessed but not captured in eCRF.  
[COMPANY_001]  Confidential  Page 19 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Section 8.3.2 
Table 8 -1 
(Footnote #2) 
 Additional information 
and update on 
histopathology assessment  Information updated (footnote #10 
removed) to separate histopathology 
(biopsy/salvage surgery) assessment (CTS level 1) in the table from the SoC diagnostic procedures performed as part of CTS level [ADDRESS_30132], biopsy/salvage surgery should be performed within 8 weeks after the [
18F]CTT1057 PET/CT scan AND after 
[68Ga]Ga -PSMA -11 PET/CT scan. SoC 
diagnostic procedures, which include at least a high resolution CT scan with intravenous and oral contrast (or MRI if CT scan with contrast is medically contraindicated), and any other SoC imaging diagnostic procedure as clinically indicated per SoC (CT/MRI, Bone Scan, etc.), should be performed within 8 weeks 
before or after [18F]CTT1057 scan.  
Section 8.3.1  
Table 8 -1 
(Footnote #9)  Terminology update 
for CT scan  Updated to remove the “low dose” 
terminology which is no longer used in clinical practice for the CT portion of 
PET/C T (transmission scan).  
Section 8.[ADDRESS_30133] results at 
screening  Updated to remove the statement that only 
central laboratory results will be used for 
assessment of participants’ eligibility to the study as any clinically significant finding from local laboratory results available for the patient should also be considered for eligibility assessment, notably for 
exclusion criterion #2.  
Section 8.4.1 
Table 8 -5 Clarification of lab tests  Updated for clarification that phosphorus laboratory parameter is phosphate 
[COMPANY_001]  Confidential  Page 20 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 (inorganic phosphorus) and that glucose is 
non-fasting glucose.  
Section 8.4.2 Clarification on ECG 
review requirements  Update to add that ECG will be locally 
collected and evaluated.  
Section 9.1 Clarification in the 
discontinuation 
definition and wordin g Update to separate discontinuation from study treatment and discontinuation from 
study.  
Section 9.1.2 Addition of section  Update to separate discontinuation from 
study treatment and discontinuation from 
study.  
Section 9.1.3 Addition of section  Update to move the section “lost to follow-
up" from “withdrawal of consent section 
9.2 added in discontinuation of study 
section.  
Section 9.2  Clarification and 
addition of new 
concept  Update to add the concept of “opposition to 
use data/biological samples” which can 
occur on top of withdrawal of consent.  
Section 9.3  Clarification on 
definition and 
requirements  Update to add specific actions to be 
performed prior early discontinuation of 
the study.  
Section 10.1.3 Clarification on SAE 
reporting  Update to emphasize reporting timelines requirements and all related 
documentation.  
Section 10.1.5 
Table 10-1  Clarification on study 
treatment errors/misuse Updated to clarify that all study treatment errors/misuse should be reported to the Sponsor. A reference to Table 10- [ADDRESS_30134] be recorded in 
AE eCRF even if not associated with an 
AE. 
Section 10.1.5 
 Terminology “abuse” 
not relevant removed  Updated to remove the terminology of abuse as this is not relevant for the PET 
imaging tracers used in this study, which are administered to patients on site by [CONTACT_30766] -
administered.  
Section [ADDRESS_30135] in the study.  
[COMPANY_001]  Confidential  Page 21 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Section 12.5.2 Clarification on lab 
values listing  Updated to indicate that clinically notable values or changes in vital signs will  be 
flagged in listings.  
All sections  Minor updates  Minor typographical corrections, removal 
of duplicated wording and minor rewording were implemented across the 
document.  
 
Protocol Summary 
Protocol 
number  CAAA405A12301  
Full Title  Phase III study for evaluation of the diagnostic performance of [18F]CTT1057 
PET imaging in patients with prostate cancer with rising PSA levels [biochemical 
recurrence (BCR)] (GuidePath)  
Brief title  Study of diagnostic performance of [18F]CTT1057 in BCR  
Sponsor and 
Clinical Phase  [COMPANY_001]  Phase III  
Investigation 
type Radiopharmaceutical  
Study type  Interventional  
Purpose and 
rationale [18F]CTT1057 is a promising novel Prostate Specific Membrane Antigen 
(PSMA) -targeting 18F-labeled Positron Emission Tomography (PET) imaging 
agent. Unlike other PSMA agents which share a urea backbone, [18F]CTT1057 is 
based on a phosphoramidate scaffold that binds
 to PSMA with high 
nanomolar 
affinity, which may account for a higher and prolonged tumour 
uptake. Together with the higher resolution of PET/Computerized Tomography 
(CT) images when using a 18F-labelled PET agent, it would therefore favor the 
identification of smaller lesions, and consequently, also at earlier stages of the 
disease. A [18F]CTT1057 Phase- I study  has shown an acceptable safety profile 
without any radiotracer -related adverse reactions, and has provided preliminary 
evidence of diagnostic performance of [18F]CTT1057 PET in detecting and 
localizing PSMA -positive tumors using pathology as standard of truth (SoT).  
The current study aims at evaluating the diagnostic performance of 
[18F]CTT1057 as a PET  imaging agent for detection and localization of PSMA 
positivity in patients diagnosed of biochemical recurrence of prostate cancer 
(PCa), using a composite truth standard.  
Primary 
Objective(s)  The co -primary objectives of this study are  
• to evaluate the region- level  correct localization rate  (CLR) of 
[18F]CTT1057 
• to evaluate the patient -level positive predictive value (with anatomical 
localization) of [18F]CTT1057 
The primary clinical question of interest is: What  is the probability that a positive 
[18F]CTT1057 PET/CT scan  truly detects and localizes (PSMA -expressing) 
tumor recurrence in BCR PCa patients?  
Secondary 
Objectives  • To evaluate the patient -level sensitivity of [18F]CTT1057 
• To evaluate the patient -level specificity of [18F]CTT1057  

[COMPANY_001]  Confidential  Page 22 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • To evaluate the patient -level negative predictive value of [18F]CTT1057 
• To evaluate the patient -level accuracy of [18F]CTT1057 
• To evaluate the region level sensitivity of [18F]CTT1057 
• To evaluate the region level specificity of [18F]CTT1057 
• To evaluate the region level negative predictive value of [18F]CTT1057 
• To evaluate the region level accuracy of [18F]CTT1057 
• To evaluate correct detection rate (CDR)  
• To evaluate detection rate  
• To evaluate the patient -level positive predictive value related to PSA levels  
• To characterize the safety and tolerability of [18F]CTT1057 
• [18F]CTT1057 scan inter -reader variability  
• [18F]CTT1057 scan intra -reader variability  
• Concordance between [18F]CTT1057 and [68Ga]Ga- PSMA -11 for detection 
of lesions at lesion level  using central reads  
• To evaluate the change in patient management plans attributed to the 
PET/CT scan  
• Assess all the above primary and secondary objectives independently in the 
subgroup of patients with prior radical prostatectomy (RP) and the subgroup 
of patients  with prior curative intent radiation therapy (RT).  
Study design This is a prospective,  open -label, multi center, single -arm Phase III study to 
evaluate the diagnostic performance of  [18F]CTT1057 as a PET  imaging 
agent  for detection and localization of  PSMA positive tumors in PCa patients 
diagnosed with biochemical recurrence (BCR) after initial definitive therapy with either radical prostatectomy (RP) or curative intent radiation therapy (RT), using 
a CTS as reference.   
The CTS  to be used as reference will be hierarchical in nature, with [ADDRESS_30136] of Truth (SoT) procedures, that will be applied as follows:  
CTS Level 1: Histopathology  if available for the lesion (from prospective biopsy 
or salvage surgery performed within 8 weeks after t he [
18F]CTT1057 PET/CT 
scan); OR in case that histopathology is not available for a lesion, inconclusive or negative (for biopsy only):  
CTS Level 2: Imaging  diagnostic procedures performed on each patient as 
clinically indicated per SoC, which must include at least a high resolution CT 
scan with contrast and a [
68Ga]Ga -PSMA- 11 PET/CT) performed within 8 weeks 
(either before or after) the [18F]CTT1057 PET/CT scan. Three -month follow -up 
imaging (from baseline) will also be used as part of the CTS level 2 in c ases 
where it is clinically required for the diagnosis of particular lesion(s); OR if 
neither of the two above are feasible or deemed appropriate or they are 
inconclusive:   
CTS Level 3: 50% or greater decline in PSA following radiation therapy (as 
long as no concomitant androgen deprivation therapy (ADT) is given) as per 
Prostate Cancer Working Group 3 (PCWG3) criteria.  
All participants will undergo 2 PET/CT  scans: one with the investigational agent 
[18F]CTT1057 and another with [68Ga]Ga -PSMA- 11 (as a component of the 
CTS Level 2 and for a secondary endpoint of  assessment of concordance 
between the 2 PET/CT  scans for detection of lesions). The [ADDRESS_30137] 14 days apart, and the PET/CT  scan 
sequence for each partici pant will be assigned at random in a 1:1 ratio.  
[COMPANY_001]  Confidential  Page 23 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Study 
population Male participants ≥ 18 years of age, with biopsy proven prostate 
adenocarcinoma and rising PSA after definitive therapy with RP or curative intent radiation therapy (external beam or brachytherapy), diagnosed of 
biochemically recurrent PCa. Approximately [ADDRESS_30138] 152 participants are evaluable (i.e. have both an evaluable [
18F]CTT1057 PET/CT scan imaging,  and at least one evaluable CTS 
assessment and have not received any prohibited systemic antineoplastic 
therapy before the completion of PET/CTs and CTS procedures)  
, which will be required for the calculation of the co -primary endpoints.   
Inclusion criteria  • Signed informed consent must be obtained prior to participation in the study  
• Biopsy proven prostate adenocarcinoma.  
• Biochemical recurrence following initial definitive therapy (with either radical 
prostatectomy or curative -intent radiation therapy) as defined:  
o by [CONTACT_30767] (AUA) criteria for patients who have 
undergone  RP: Initial serum PSA of ≥0.2 ng/mL  measured at least 6 
weeks after RP with a second confirmatory persistent PSA  level of >0.2 
ng/mL, or   
o  by [CONTACT_30768] (ASTRO)- Phoenix cr iteria 
for patients who have undergone curative- intent  RT: Rise of serum PSA 
measurement of 2 or more ng/mL above the nadir PSA observed post RT. 
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2 
• Participants must be adults ≥ 18 years of age  
Exclusion 
criteria  • Inability to complete the needed investigational and standard -of-care 
imaging examinations due to any reasons (severe claustrophobia, inability to 
lie still for the entire imaging time, etc.)  
• Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opi[INVESTIGATOR_684], would indicate a significant risk to safety or impair study 
participation,  including, but not limited to, current severe urinary 
incontinenc e, hydronephrosis, severe voiding dysfunction, need of 
indwelling/condom catheters, [LOCATION_001] Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and Coronavirus Disease 
2019 (COVID -19) 
• Prior major surgery undergone less than 12 weeks prior to screening (with 
the exception of any surgery related to prostatic cancer)  
• Known allergy, hypersensitivity, or intolerance to [
18F]CTT1057, [68Ga]Ga -
PSMA- 11, or to CT  contrast   
• Prior and current use of PSMA targeted therapi[INVESTIGATOR_014]  
• Prior ADT (first or second generation), including Luteinizing Hormone-Releasing Hormone (LHRH) analogues (agonists or antagonists) within 9 months before screening  
• Any 5 -alpha reductase inhibitors within 30 days before screening  
• Use of other investigational drugs within 30 days before screening  
• Castration -resistant patients  
• Patients with small cell or neuroendocrine PCa in more than 50% of biopsy tissue  
• Prior salvage surgery or salvage radiation therapy  
[COMPANY_001]  Confidential  Page 24 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Study 
treatment  The term “Study Treatment” indicates the administration of at least one of the 
two PET imaging agents:  [18F]CTT1057 and [68Ga]Ga -PSMA- 11 independently 
of whether the PET/CT  scans were acquired or not  
Treatment of  
interest In this study, the investigational imaging agent of interest is [18F]CTT1057, 
injected as a single intravenous dose of approximately 370 Mega-
Becquerel  (MBq)  and subsequent PET/CT  scan.   
Efficacy 
assessments Hierarchical CTS  with 3 levels:  
• Level  1: Histopathology assessments  
• Level 2: Imaging diagnostic assessments: at least a high- resolution CT with 
contrast and a [68Ga]Ga- PSMA -11 PET/CT. Other SoC imaging modalities if 
clinically indicated. Imaging data will be read centrally  
• Level 3: PSA assess ments  
[18F]CTT1057 PET/CT assessments, read centrally  
Key safety assessments • Adverse Events (AEs)  
• Serious Adverse Events (SAEs)  
• Vital signs, physical examinations  
• Electrocardiograms (ECGs)  
• Laboratory parameters including hematology, clinical chemistry  
• Concomitant medications and/or therapi[INVESTIGATOR_30746]  • Patient management questionnaire for secondary endpoint to evaluate the 
change in patient management plans attributed to the PET/CT scan  
Data analysis The following data analyses are planned for the study:  
The co -primary endpoints of the study are region -level CLR and patient -level 
Positive Predictive Value (PPV)  
• Region- level CLR is defined as the proportion of regions containing at least 
one true positive (TP) lesion (exactly localized correspondence between 
PET imaging and the reference standard), regardless of any co -existent 
false positive (FP) findings within the same region, out of all regions 
containing at least one PET -positive finding.  
Region- level CLR and its 95% confidence interval (CI) will be calculated using 
logistic random -effects models taking into account the correlation among regions 
within one patient. The lower bound of the 95% CI for  CLR should be greater 
than 0.[ADDRESS_30139] co -primary endpoint.  
• Patient -level PPV is defined as the proportion of patients who have at least 
one TP lesion (exactly localized correspondence between PET imaging and 
the reference standard), regardless of any co-existent FP findings, out of all patients who are PET/CT  scan  positive. Patient -level PPV and its 95% 
CI will be calculated based on the binomial distribution. The lower bound of 
the 95% CI for patient -level PPV should be greater than 0.2 to attain the 
second co -primary endpoint.  
Analyses for co- primary endpoints will be based on the efficacy analysis set 
(EFF).  
Centralized imaging assessments (CTS  Level 2) will be used as reference 
standard if pathology (CTS  Level 1) is not available for a lesion, inconclusive or 
negative  (for biopsy only) . 
[COMPANY_001]  Confidential  Page 25 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Other secondary endpoints including patient -level sensitivity, patient- level 
specificity, patient -level negative predictive value, patient -level accuracy, patient -
level correct detection rate, patient -level detection rate, [18F]CTT1057 scan inter -
reader agreement, [18F]CTT1057 s can intra- reader agreement, change in patient 
management plans, region- level sensitivity, region -level specificity, region -level 
negative predictive value, region -level accuracy, concordance between 
[18F]CTT1057 and [68Ga]Ga- PSMA- 11 will also be analyzed. Detailed statistical 
methodology for these analyses will be provided in the statistical analysis plan 
(SAP).  
Key words  [18F]CTT1057, [68Ga]Ga- PSMA- 11, PET/CT, Radioligand, Imaging, BCR, CTS, 
PCa  
 
1 Introduction  
1.1 Background 
Prostate- specific membrane antigen (PSMA) and prostate cancer  
Prostate- specific membrane antigen is a transmembrane protein, also known as folate hydrolase 
or glutamate carboxypeptidase II. PSMA is highly overexpressed on the tumor cells of prostate 
adenocarcinomas ( Hupe et  al 2018, Bravaccini  et al 2018 ), and has also been reported to be 
overexpressed on tumor cells and tumor -vasculature of endomet rial and ovarian cancer 
(Wernicke et  al 2017 ), and mainly on tumor -vasculature of a variety of other cancer types such 
are breast ( Tolkach et al 2018), colorectal, gastric (Haffner et  al 2009), glioblastoma ( Wernicke 
et al 2011, Tanjore Ramanathan et al 2020), kidney ( Spatz et al 2018 ), liver (Tolkach et al 
2019), lung ( Wang et al 2015, Schmidt et al 2017 ) and pancreatic cancer ( Stock  et al 2017 ). 
PSMA has restricted and several hundred -fold lower expression than PCa  cells in some normal 
tissues such as the duodenal mucosa, proximal renal tubules, and salivary glands ( Bostwick et 
al 1998, Ghosh and Heston 2004).  
From all the above named PSMA -overexpressing tumors, PCa is the one in which the role of 
PSMA has been most extensively studied. PCa  remains the cancer with the second highest 
mortality in the [LOCATION_002] (US),  and the third leading cause of cancer -related death in 
Europe in men ( Siegel  et al 2017, Malvezzi  et al 2019). It also remains the most diagnosed 
cancer with an estimated increase of 9,960 new cases with a total of 174,650 in 2019 (Siegel  et al 2018, Siegel  et al 2019 ). Most of the diagnosed cases are in more developed 
regions due to the use of PSA testing, but there is only modest variation in mor tality rates 
globally which is driven by [CONTACT_30769], and often castration- resistant disease 
(Bray  et al 2013).  Subsequent treatment is multifaceted and may involve observation, surgery 
(prostatectomy), radiation therapy (external beam or brachytherapy), hormonal therapy, chemotherapy, and in the future, radioligand therapy ( Oh and Kantoff 1999, Roscigno et al 
2005, Jani 2006). Prostate -specific membrane antigen overexpression correlates with advanced, 
high- grade, metastatic, androgen -independent disease ( Ross  et al 2003). The differential 
expression of PSMA from tumor to non- tumor tissue has resulted in numerous targeted 
strategies involving both disease localization using PSMA -PET imaging as well as therapeutic 
intervention. Correct identification of disease location and e xtent determines treatment 
[COMPANY_001]  Confidential  Page 26 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 decisions for patients with PCa. Identification of distant metastatic disease at the early stages 
of PCa is important in planning PCa management. There is increasing evidence that primary landing sites for PCa lie outside the template of an extended pelvic lymph node dissection (ePLND). Primary lymph node landing sites outside an ePLND have been reported in 47.7% of men with suspected node- positive disease on 
68Ga-PSMA PET/CT ( Yaxley  et al 2019a ). This 
is very important, as the morbidity of a surgery could be avoided, given the change in management from one of curative intent, to management that will require a multimodality approach after treatment of the prostate primary tumor (Yaxley  et al 2018, Yaxley  et al 2019b).  
Up to 40% of the patients with PCa develop biochemic al recurrence (BCR) within 10 years 
after initial treatment (Isbarn  et al 2010). Usually an increase of the PSA -level precedes a 
clinically detectable recurrence by [CONTACT_30770] ( Van Poppel et  al 2006 ). However, it cannot 
differentiate between local, regional or systemic disease with the necessary precision that is essential for further disease management ( Bott 2004).  
It is relevant, therefore, to detect smaller and distant lesions as early as possible.  With the 
emergence of PSMA -targeted radioligand therapy, in addition to early diagnosis, it is useful to 
diagnose PSMA -positivity to determine the future use of radioligand therapy. This is now 
becoming a reality since the recent approval of  [
68Ga]Ga -PSMA -11 in the [LOCATION_003] (December 
2020) as a radioactive diagnostic PET imaging agent in men with PCa with suspected metastasis who are candidates for initial definitive therapy , or with suspected recurrence based on elevated 
serum PSA level ( [
68Ga]Ga -PSMA -11 USPI ).  However, despi[INVESTIGATOR_30747] 
[68Ga]Ga -PSMA -11, its practical use at scale is limited by [CONTACT_30771] -life of [68Ga], which 
requires radiolabeling in close proximity to the point of care. Moreover, the yield of currently available [
68Ga] generators limits the manufacturing of the number of doses required to address 
the growing population of PCa patients. This gap between the unmet need and availability is expected to widen, as radioligand therapy options are available for treatment. While solid target using cyclotrons (currently unapproved for clinical use) can generate greater quanti ties 
of [
68Ga], and thereby [CONTACT_30772], the geographical reach of the few cyclotrons coupled with 
the short half- life of [68Ga] would still leave this need unaddressed.  
Positron Emission Tomography (PET) imaging in prostate cancer  
The usual diagnostic tools for PCa include PSA testing, digital rectal palpation, transrectal ultrasound, prostate biopsy, and histopathologic examination ( Schwarzenböck  et al 2012, 
Smith  et al 2016, Prasad  et al 2016 ). Additionally, further imaging techniques such as 
Magnetic Resonance Imaging (MRI), bone scintigraphy, CT, and [
18F]Fluorodeoxyglucose 
(FDG), [18F]Choline, [11C]Choline and the more recently approved [18F]fluciclovine 
(Nanni et  al 2016, Odewole et  al 2016) PET/CT are used for staging primary PCa and restaging 
biochemical recurrences ( Schwarzenböck et  al 2012).  CT and MRI are the standard of care 
imaging procedures for measuring tumors at baseline and lesions selected for response assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenha uer et al 2009 ). However, these imaging modalities have shown limited yielding in the 
staging of PLN in patients with PCa. A meta -analysis showed pooled sensitivities of 0.42 (95% 
CI 0.26-0.56) for CT and of 0.39 (95%  CI 0.22- 0.56) for MRI ( Hövels et al 2008 ). Therefore, 
more sensitive and accurate imaging tests than the currently available standard -of-care 
examinations are needed ( Hricak  et al 1987, Shinohara et  al 1989, Scheidler et al 1999 , 
[COMPANY_001]  Confidential  Page 27 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Blomqvist et  al 2014 ). Novel PET radiotracers promise to overcome this limitation. PET 
imaging is an enticing choice as it offers the potential to both stage patients and provide insi ght 
into tumor biology. Among the various PET probes available, 68Ga-labeled ligands of the 
PSMA were associated with unprecedented accuracy and effect on treatment in several meta-
analyses of retrospective studies ( Perera et al 2016, Han et al 2018, Von Eyben et al 2018). 
Recent studies reported that 68Ga-labeled PSMA PET/CT has excellent detection rates for 
lymph node metastases, skeletal metast ases, local relapses, and soft -tissue metastases compared 
with other PET tracers such as 18F- and 11C-labeled choline derivatives ( Afshar -Oromieh et al 
2013, Afshar -Oromieh et al 2014, Ceci et al 2015 , Eiber et al 2015, Budäus et al 2016).  
Several head to head comparison studies have been performed on the uptake of [
18F]Fluciclovine vs [68Ga]Ga -PSMA -11 for localization of PCa  BCR. Detection rates were 
superior for [68Ga]Ga -PSMA -11 vs [18F]Fluciclovine after RP in patients with PSA < 2.0 ng/ml 
on per -patient and per -region basis ( Calais et  al 2018). However, a larger prospective head -to-
head comparison study on [18F]Fluciclovine vs [68Ga]Ga -PSMA -11 in patients with BCR of 
PCa found no statistical differences in the overall detection rate for PCa recurrence between the two different radioligands ( Pernthaler  et al 2019 ). The differences between these studies may 
be attributed to various factors, including but not limited to sample size differences, differences in PSA levels of median values of < 2.0 ng/ml vs  14.9 ng/mL, time between scanning sessions, 
and standardization of the imaging study protocols. 
Fluciclovine is a synthetic amino acid, which is transported across cell membranes by [CONTACT_30773], such as L -Type Amino Acid 
Transporter 1 (LAT- 1) and Alanine Serine Cysteine Transporter 2 (ASCT2). [
18F]Fluciclovine 
uptake is not specific for PCa and may occur in other cancer types. In addition, the lack of 
selectivity for PCa may contribute to false -positive cases, which may be associated with 
inflammatory responses to therapeutic interventions. Contrarily, radioligands selective for the 
PSMA, such as [68Ga]Ga -PSMA -11, provide greater sensitivity and specificity for imaging 
patients with PCa.  
[18F]CTT1057: A promising investigational PSMA- PET radiotracer  
Most experts in the field agree, the future of PSMA -based PET imaging will be with  18F-labeled 
tracers because of the practical advantages:  18F has a longer half -life than  68Ga, which enables 
the tracers to be distributed to PET centers without a cyclotron and to be easily handled in clinical routine. In addition, the higher positron decay branching of  
18F (96.9%) versus  68Ga 
(87.7%), together with the shorter positron range of 18F, account to the higher PET imaging 
resolution achieved with  18F-labeled radiopharmaceuticals ( Conti and Eriksson  2016). 
[18F]CTT1057 is a promising novel PSMA -targeting  18F-labeled PET imaging agent. Unlike 
most other PSMA agents labelled with either  68Ga or  18F (e.g. [68Ga]Ga -PSMA -11, 
[18F]PSMA1007, [18F]DCFPyL) which share a urea backbone, [18F]CTT1057 is based on a 
phosphoramidate scaffold that binds 
to PSMA with high nanomolar affinity, which 
may acc
ount for a higher and prolonged tumor uptake ( Behr  et al 2019).
 Together with the 
higher resolution of PET images when using a 18F-labelled PSMA agent, it would therefore 
favor the identification of smaller lesions, and consequently, also at earlier stages of the disease.  

[COMPANY_001]  Confidential  Page 28 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 A [18F]CTT1057 Phase -I study in 20 PCa patients ( n = 5 primary staging and n = 15 m etastatic-
castration resistant prostate cancer (mCRPC)) ( Behr  et al 2019) has shown an acceptable safety 
profile without any radiotracer -related adverse reactions. The biodistribution o f [18F]CTT1057 
in humans is similar to that of other PSMA -targeted agents, and exposure rates of [18F]CTT1057 
are also similar to those of the urea -based PET compounds with the advantageous exception of 
lower exposure to kidneys and salivary glands. Prelim inary evidence of diagnostic performance 
of [18F]CTT1057 PET in detecting and localizing PSMA -positive tumors was provided from 
the n=[ADDRESS_30140] of truth (SoT). 
Abnormal [18F]CTT1057 PET uptake corresponding to the pathology- proven cancer was shown 
in [ADDRESS_30141] PSA in the cohort. The Phase -I study also demonstrated that metastatic lesions are 
detected with higher sensitivit y on  [
18F]CTT1057  imaging than on conventional imaging 
(Behr  et al 2019). Another smaller study showed that the image quality on [18F]CTT1057 PET 
imaging was qualitatively similar to tha t obtained on [68Ga]Ga -PSMA -11 PET 
(Behr  et al 2017).  
Further details on [18F]CTT1057  can be found in the Investigator's Brochure (IB). 
1.2 Purpose 
The current study aims at evaluating the d iagnostic performance of [18F]CTT1057 as a 
PET imaging agent for detection and localization of PSMA positivity in patients diagnosed of biochemical recurrence of PCa , using a composite truth standard. 
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• Evaluate the region- level  correct 
localization rate  (CLR) of [18F]CTT1057  • Proportion of regions containing at least one TP lesion (anatomically localized 
correspondence between PET imaging and 
the reference standard), regardless of any co-
existent FP findings within the same region, 
out of all regions containing at least one PET -
positive finding by [CONTACT_30774]. See 
Section  2.1 for Primary Estimand  
• Evaluate the patient -level positive 
predictive value (with anatomical 
localization) of [18F]CTT1057  • Proportion of patients who have at least one TP lesion (anatomically localized correspondence between PET imaging and 
the reference standard), regardless of any co-
existent FP findings, out of all patients who are PET/CT  scan positive by [CONTACT_30775]. See  Section  2.1
 for Primary 
Estimand  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
[COMPANY_001]  Confidential  Page 29 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Objective(s)  Endpoint(s)  
• Evaluate the patient -level sensitivity of 
[18F]CTT1057  • Proportion of patients that test positive on 
[18F]CTT1057 and CTS (TP) among those 
that are CTS positive (TP or FN)  
• Evaluate the patient -level specificity of 
[18F]CTT1057  • Proportion of patients that test negative on [
18F]CTT1057and CTS (TN) among those that 
are CTS negative (TN or FP)  
• Evaluate the patient -level negative 
predictive value  of [18F]CTT1057  • Proportion of patients who are both 
[18F]CTT1057 and CTS negative (TN) among 
those who test negative on [18F]CTT1057 (TN 
or FN)  
• Evaluate the patient -level accuracy of 
[18F]CTT1057  • Proportion of patients that are CTS and [
18F]CTT1057 positive (TP) and negative (TN) 
among those patients that identified on 
[18F]CTT1057 (TP, TN, FP or FN)  
• Evaluate correct detection rate (CDR)  • Proportion of patients who have at least one 
TP lesion (exactly localized correspondence 
between PET imaging and the reference standard), regardless of any co- existent FP 
findings, out of all patients who are scanned  
• Evaluate detection rate  • Proportion of patients who have at least one PET positive lesion, regardless of TP or FP 
findings, out of all patients who are scanned  
• Evaluate the region level  sensitivity  of 
[18F]CTT1057  • Proportion of regions that test positive on both 
[18F]CTT1057 and CTS (TP) among those 
regions that are CTS positi ve (TP or FN)  
• Evaluate the region level  specificity  of 
[18F]CTT1057  • Proportion of regions that test negative on 
both [18F]CTT1057 and CTS (TN) among 
those regions that are CTS negative (FP, or 
TN) 
• Evaluate the region level  negative 
predictive value  of [18F]CTT1057  • Proportion of regions that are CTS and [
18F]CTT1057 negative (TN) among those 
regions that test negative on [18F]CTT1057 
(TN or FN)  
• Evaluate the region level  accuracy of 
[18F]CTT1057  • Proportion of regions that are CTS and [
18F]CTT1057 positive (TP) and negative (TN) 
among those regions that identified on 
[18F]CTT1057 (TP, TN, FP and FN)  
•  Evaluate the patient -level positive 
predictive value related to PSA levels  • Percentage of patients who have at least one TP lesion (exactly anatomically localized 
correspondence between [
18F]CTT1057 PET 
imaging and the reference standard), 
regardless of any co- existent FP findings, out 
of all patients who are [18F]CTT1057 positive, 
stratified by [CONTACT_30776]  
• Characterize the safety and tolerabi lity of 
[18F]CTT1057  • Incidence of AEs  Treatment emergent 
adverse event (TEAE) rate within 14 days 
after each PET tracer administration  
[COMPANY_001]  Confidential  Page 30 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Objective(s)  Endpoint(s)  
• [18F]CTT1057 scan inter -reader variability   • Inter-reader agreement of [18F]CTT1057 
images  
• [18F]CTT1057 scan intra -reader variability   • Intra-reader agreement of [18F]CTT1057 
images  
• Concordance between [18F]CTT1057 and 
[68Ga]Ga- PSMA- 11 for detection of lesions 
at lesion level using central reads  • Concordance between [18F]CTT1057 and 
[68Ga]Ga- PSMA- 11  for detection of PSMA-
positive lesions (location and number) using 
central reads  
• Evaluate the change in patient 
management plans attributed to the PET/CT scan
 • Percentage of patients who underwent a change in intended treatment plan attributed to the PET/CT scan as assessed by [CONTACT_30777]  
• Assess all the above primary and secondary objectives independently in the 
subgroup of patients  with prior radical 
prostatectomy and the subgroup of patients   with prior curative intent radiation 
therapy  • All the a bove primary and secondary 
endpoints independently in the subgroup of patients with prior RP  and the subgroup of 
patients with prior curative intent radiation 
therapy
 

[COMPANY_001]  Confidential  Page 31 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 2.[ADDRESS_30142] is: What is the probability that a positive [18F]CTT1057 
PET/CT scan  truly detects and localizes (PSMA -expressing) tumor recurrence in BCR PCa 
patients?  
The justification for the primary estimand is that we wish to assess the diagnostic performance 
of [18F]CTT1057 PET/CT in detecting and localizing PSMA positivity in PCa patients 
diagnosed of biochemical recurrence (BCR), which represents a stage of PCa where there is an increase in PSA levels after initial treatment. Correct identification of disease location and extent guides treatment decisions. It is relevant, therefore, to detect smaller lesions as early as possible. Sensitivity and specificity of [
18F]CTT1057 PET/CT in detecting and localizing 
PSMA positivity using histopathology as SoT will be assessed in an independent study in newly 
diagnosed high- risk PCa patients candidate to surgery. However, in this primary  staging 
population a low prevalence and high variability of metastatic lymph nodes has been reported 
(from 4 -58%) (Petersen  and Zacho  2020). Therefore, an additional study in the BCR  setting is 
needed, since this is a relevant patient population which is expected to have an adequate representation of metastasis- positive and metastasis -negative patients by [CONTACT_30778]. In this population, a CTS  is needed for reference (for CTS  details see 
Section  3 and Section  4.1). Pathology is available in only a limited number of cases, and 
morphological imag ing is negative in a substantial number of cases. This makes the 
identification of true and false negative results a challenge, thus complicating the evaluation of sensitivity and specificity. Therefore, the region- level correct localization rate (CLR) defined 
as the region -level PPV with anatomical localization and the patient- level PPV with anatomical 
localization are more appropriate co -primary endpoints than sensitivity and specificity in the 
BCR setting. The patient -level PPV with anatomical localization, as the conditional probability 
of positivity given the result of the PET/CT scan is more meaningful than the correct detection rate (CDR) defined as the percentage of true -positive patients in the whole population 

[COMPANY_001]  Confidential  Page 32 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 (unconditional probability of positivity). Moreover, the CDR  has reported to be dependent of 
the PSA  levels in the BCR population using another [18F]-PSMA  labeled PET  agent 
(Chantadisai  et al 2020 ). 
The primary estimands are described by [CONTACT_6570]:  
Primary estimand 1:  
1. Population: Patients with biopsy proven prostate adenocarcinoma and rising PSA after 
definitive therapy with RP or curative -intent ra diation therapy (external beam or 
brachytherapy), diagnosed of biochemically recurrent PCa. Further details about the population are provided in Section  5. 
2. Variable: Proportion of regions conta ining at least one TP lesion (anatomically localized 
correspondence between [
18F]CTT1057 PET imaging and the reference standard), 
regardless of any co -existent FP findings within the same region, out of all regions 
containing at least one [18F]CTT1057 PET-positive finding, using central readings 
3. Treatment of interest: [18F]CTT1057 injected as a single intravenous dose of 
approximately 370 MBq and subsequent PET/CT scan. Further details about the investigational treatment is provided in Section  6. 
4. Handling of remaining intercurrent events: Patients who received the investigational imaging agent [
18F]CTT1057  but did not undergo/complete the PET scan for any reasons 
(e.g. consent withdrawal, PET cam era failures, etc.) Details on how to handle intercurrent 
events are provided in Section  12.4.3. 
5. Summary measure: Estimate of proportion  of regions containing at least one TP lesion 
(anatomically localized correspondence between [18F]CTT1057 PET imaging and the 
reference standard), regardless of any co -existent FP findings within the same region, out 
of all regions containing at least one [18F]CTT1057 PET-positive finding (CLR) and CLR 
along with 95% CI estimated using logistic random -effects models taking into account the 
correlation among regions within one patient.   
Primary estimand 2:  
1. Population: the same as primary estimand 1  
2. Variable:  Proportion of patients who have at least one TP l esion (anatomically localized 
correspondence between [18F]CTT1057 PET imaging and the reference standard), 
regardless of any co -existent FP findings, out of all PET positive patients, using central 
readings. 
3. Treatment of interest: the same as primary estimand 1  
4. Handling of remaining of intercurrent events: the same as primary estimand 1  
5. Summary measure:  Estimate of proportion of patients who have at least one TP lesion 
(anatomically localized correspondence between [18F]CTT1057 PET imaging and the 
reference standard), regardless of any co -existent FP findings, out of all patients who are 
PET/CT scan positive (PPV) and  PPV along with 95%  CI estimated using binomial 
distribution. 
[COMPANY_001]  Confidential  Page 33 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 2.2 Secondary estimands  
Not applicabl e  
3 Study design  
This is a prospective,  open -label, multi center, single -arm Phase III study to evaluate the 
diagnostic performance of  [18F]CTT1057 as a PET  imaging agent  for detection and localization 
of PSMA positive tumors in PCa patients diagnosed with biochemical recurrence (BCR) after 
initial definitive therapy with either RP or curative- intent RT, using a CTS as reference.   
Approximat ely [ADDRESS_30143] 152 participants are evaluable 
for the co -primary endpoints. [18F]CTT1057 PET/CT scan imaging will be read in a central 
Contract Research Organization (CRO)  by 3 independent nuclear medicine physicia ns who will 
be blinded to any other patient data. See Section  4.1 and Section  8.3.1 for central read details.  
The CTS to be used as reference will be hierarchical in nature, with 3 levels of SoT procedures that will be applied as follows:  
 Level 1)  
• Histopathology if available for a lesion (from prospective biopsy or salvage surgery performed within 8 weeks after the [
18F]CTT1057 PET/CT scan); OR in case that 
histopathology is not available for a lesion, inconclusive (i.e. if biopsy/surgery tissue sample is not evaluable for histopathology assessment due to  sample quality or inadequate quantity or any other technical causes) or negative (for biopsy only): 
Level 2)  
• Imaging diagnostic procedures performed on each patient as clinically indicated per SoC, which must include the [
68Ga]Ga -PSMA -11 PET/CT scan that is mandatory for all 
subjects randomized in the study and at least  a high resolution CT scan (covering at least 
chest, abdomen, and pelvis and any other region as clinically indicated) with intravenous and oral contrast (or MRI if CT scan with contrast is medically contraindicated).  The high resolution CT scan and any other imaging diagnostic procedure clinically indicated as per SoC must be acquired within the 8 weeks either prior to or following the [
18F]CTT1057 
PET/CT scan. Three -month follow- up imaging (from baseline) will also be used as part of 
the CTS level 2 in cases where it is clinically required for the diagnosis of particular lesion(s); OR if neither of the two above are feasible or deemed appropriate or they are inconclusive (i.e. i mages are not interpretable due to poor or inadequate image quality that 
precludes reliable assessment) :  
Level 3)  
• 50% or greater decline in PSA following radiation therapy  (as long as no concomitant 
androgen deprivation therapy (ADT) is given) as per PCWG3 criteria ( Scher  et al 2016).   
In the cases where pathology will be available, assessments by [CONTACT_30779], and results should be available within 2 weeks after surgery. Pathologists will be blinded to any PSMA -PET data (i.e. both PET/CT scans). In this case, only pathology 
will be used as SoT for the concerned lesion(s).   
[COMPANY_001]  Confidential  Page 34 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 In the cases where pathology will not  be available for a lesion, the central read results of the 
[68Ga]Ga -PSMA -11 PET/CT scan (performed for all subjects randomized) and other imaging 
diagnostic procedures to be performed on each participant for the CTS  level 2 will be used as 
SoT for the co-primary endpoint calculations. See Section  4.1 for central read details.  
All patients will undergo a  [68Ga]Ga -PSMA -11 PET/CT as part of the study, for both the CTS 
Level 2 (in case it  is required as SoT)  and the secondary endpoint of assessment of concordance 
between [18F]CTT1057 and [68Ga]Ga -PSMA -11 for detection of lesions (as detailed 
in Section  2). 
In addition to central r eview, local review of SoC images (including [68Ga]Ga -PSMA -11) will 
be performed to be used by [CONTACT_1963]/Clinical Study Investigator for patient 
management decisions and overall assessment.  
See Section  8.3.1 for assessment details and Section  6.4 for blinding requirements.  
A questionnaire on the planned patient management will be filled -in by [CONTACT_30780]/Cli nical Study Investigator before (questionnaire 1) and within 14 days after 
(questionnaire 2) knowing the results of the [18F]CTT1057 PET/CT scan. A  local review of 
[18F]CTT1057 PET/CT images will also be performed by a local nuclear medicine physician or 
radiologist with expertise in reading oncology PET/CT scans  and the results will be provided 
to the treating physician/Clinical Study Investigator for completion of questionnaire 2. Options will be given in the questionnaire to capture possible manageme nt plan, such as Surgery, 
Radiation alone, Radiation alone with change in radiation treatment plan (only applicable for questionnaire 2), Radiation plus ADT, ADT alone, Observation/surveillance, Other (free text box). Any change in patient management plan between the questionnaire 1 and questionnaire 2 should not be based only on [
18F]CTT1057 PET/CT scan results since this is an investigational 
diagnostic imaging product. Other diagnostic procedures should be performed as per SoC in order to confirm and implement the changed management plan. See Figure 3-1 for study design 
schema.  
Figure 3-1 Study Design 
 
[COMPANY_001]  Confidential  Page 35 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Screening period  
Written informed consent form (ICF) must be obtained prior to any screening procedures. The 
participant must be registered in the Interactive Response Technology (IRT)  for screening . All 
procedures described in the Assessment Schedule as per Table [ADDRESS_30144] PET imaging day (Day 1). Eligibility must then be confirmed at the latest on Day -14. The screening period should last up to 28 days. 
Once eligibility is confirmed, the participants will be randomized in IRT to be assigned to one 
of the follo wing two PET/CT scan sequences at random in a 1:1 ratio: 
• Sequence 1: [
18F]CTT1057 on Day 1 (investigational imaging agent of interest) followed 
by [68Ga]Ga -PSMA -[ADDRESS_30145] 14 days apart (as part of CTS if required, and for 
secondary endpoint)  
• Sequence 2: [68Ga]Ga -PSMA -11 (as part of CTS if required, and for secondary endpoint) 
on Day 1 followed by [18F]CTT1057  (investigational imaging agent of interest) at least [ADDRESS_30146] on each PET imaging day.  
Both visits will also be considered as the End of Treatment (EOT) visits.  
Safety Checks  
All treated participants will be contact[CONTACT_30781] 24 to 72 hours following each PET/CT scan in order to capture potential occurring Adverse Events. 
Safety Follow- up 
Participants will come back to the hospi[INVESTIGATOR_307] 14 days (+ 3 day window) after each PET/CT scan 
day, for a safety visit including vital signs, lab and urine analysis. For participants undergoing surgery, radiation therapy or initiating any antineoplastic medication (provided all CTS procedures have been completed before this initiation) prior to planned safety visit, these safety follow -up assessments will need to be performed before the surgery/radiation therapy/initiation 
of antineoplastic medication.  
Additional Follow -up 
Additional follow up period will be applicable where additional diagnostic procedures are to be 
performed. These may include SoC pathology, imaging or other modality disease assessments (CTS Levels 1 or 2)  up to 8 weeks after  [
18F]CTT1057 PET/CT scan or three -month follow -up 
imaging (from baseline) where it is clinically required for the diagnosis of particular lesion(s).  
In addition, in cases where the CTS Level 2 is not feasible/appropriate or inconclusive, and the CTS Level 3 w ill apply and will include the assessment of PSA levels prior to starting 
RT (which should commence within 8 weeks of completing [
18F]CTT1057 PET/CT scan) 
and at approximately [ADDRESS_30147] day of radiation.  
[COMPANY_001]  Confidential  Page 36 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 4 Rationale  
4.1 Rationale for study design  
In this  study, a single -dose of the radiopharmaceutical  [18F]CTT1057 (investigational imaging 
agent) will be administered intravenously, in an open-label, single-arm design.  
[18F]CTT1057 PET/CT results will be compared to the applicable SoT from the corresponding 
level of the CTS (as described in Section  3) for calculation of the co -primary endpoints and the 
diagnostic performance yielding secondary endpoints. Novel imaging agents are routinely evaluated comparing imaging results with histopathological 
findings. In the BCR setting, pathology is expected to be available only in approximately 35 -
40% of the patients, and in a subset of the lesions ( Fendler et  al 2019). Therefore, a combination 
of conventional diagnosis procedures, relying on a combination of biopsy (when possible), imaging procedures, and clinical follow up or changes in biomarkers such as PSA  levels, 
collectively know n as the composite truth standard (CTS), has been used to evaluate the 
diagnostic accuracy of new diagnostic agents in BCR patients. This methodology has limitations as the ascertainment of CTS may be subject to non -homogeneous evaluation 
between subjects as biopsy may not be feasible in all patients with metastatic lesions. Therefore, diagnosis based on CTS in the majority of the patients relies on conventional imaging, mainly morphological imaging procedures which are based on the detection of changes in lesion's size 
and has limitations, including the inability to detect smaller lesions accurately. Accordingly, for lesions that cannot be subjectively characterized on a single CT/MRI scan, serial follow up scans are obtained in order to observe changes in the morphology over time. Serial CT/MRI scans may, therefore, increase the accuracy of diagnosis of smaller, doubtful lesions observed on a single scan at the expense of time.  However, in the proposed BCR population, conventional 
imaging will be negative in a substantial proportion of cases ( Hövels et al 2008 ). Since its 
introduction in 2012, [
68Ga]Ga -PSMA -[ADDRESS_30148] studied PSMA PET agent to date. It has 
been widely used in clinical practice on a compassionate use basis and reported in prospective studies and numerous retrospective case series ( AfsharOromieh  et al 2015, AfsharOromieh et 
al 2017, Fendler et al 2019). It has also demonstrated high sensitivity in detecting PSMA 
positivity when comparing its diagnostic  accuracy with histopathologic findings in these 
patients ( Fendler et  al 2019). Based on this body of evidence, and given the recent approval of 
[
68Ga]Ga -PSMA -11 in the [LOCATION_003] ( [68Ga]GaPSMA11  USPI ), it can be used to significantly 
enhance and address the limitations of routinely used CTS for the evaluation of new diagnostics. Given the acknowledged lack of optimal reference standard in patients with biochemical recurrence (BCR)  in cases where pathology is not available,  [
68Ga]Ga -PSMA -11 PET/CT will 
provide a validated approximation to the truth, for new, upcoming PSMA -PET imaging agents 
that overcome the 68Ga production and delivery hurdles. In this study, the CTS imaging 
component (CTS Level 2) must include at least a high resolution CT scan with i.v. and oral contrast (or MRI if CT scan with contrast is medically contraindicated) and a [
68Ga] Ga-PSMA -
11 PET/C T scan. Given that in the proposed BCR population, morphological imaging has been 
reported to be negative in a substantial proportion of cases ( Hövels et  al 2008), the recently 
approved [68Ga]Ga -PSMA -[ADDRESS_30149] of truth. 
In addition, any other imaging diagnostic procedures clinically indicated for each patient as per 
[COMPANY_001]  Confidential  Page 37 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 SoC will be included in the CTS Level 2). An 8 -week time window before and  after the 
investigational PET/CT scan is proposed for the performance of the imaging diagnostic 
component of the CTS Level 2, since no major changes in the disease are expected within this timeframe.   
Anatomically localized positive lesions in [
18F]CTT105 7 PET/CT and the applicable SoT from 
the hierarchical CTS will be considered true positives for the region -level correct localization 
rate (CLR, i.e. region -level PPV)  and patient -level PPV calculations as the co -primary 
endpoints of the study.  
In the ca ses where pathology will be available, it will be used as SoT (CTS  Level 1). Pathology 
may be available in case of identified lesions that can be either biopsied or suitable for salvage 
surgery (in case of solitary or few localized lymph nodes). Local path ologists who will be 
blinded to any PSMA -PET data (i.e. both PET/CT scan results) will assess the tissue specimens 
as per SoC (see Section  6.4 for blinding details)  
If pathology is not available for a lesion, inconclusive or negative (for biopsy only), CTS  Level 
2 (imaging diagnostic procedures) will be used as SoT. These must include at least a high -
resolution CT scan with i.v. and oral contrast (or MRI if CT scan with contrast is  medically 
contraindicated) and a[68Ga]Ga -PSMA -11 PET/CT scan, but will include also any other 
imaging diagnostic procedures clinically indicated for each patient as per SoC. In order to reduce variability of image readings across multiple study sites, a centralized r eading of these 
imaging diagnostic procedures will be performed in a CRO by 3 readers who will be blinded to [
18F]CTT1057 PET/CT scan results, but not to other patient data. The majority rule (2/3 readers) 
will be used as a final outcome of the reads. Furt her details will be provided in the imaging 
charter. See also Section  6.[ADDRESS_30150] CTS  components (i.e. pathology or imaging) are feasible, conclusive 
or deemed appropriate, then CTS Level 3 (50% or greater decline in PSA following radiation therapy (as long as no concomitant  androgen deprivation therapy (ADT) is given) as per 
PCWG3 criteria) will be used as SoT. The lesion on the [
18F]CTT1057 PET/CT scan that was 
irradiated will be classified as a TP in case of ≥50% PSA decrease 3 months after RT, or as FP 
otherwise.  
A central read of the [18F]CTT1057 PET/CT scans will be performed at a CRO by [CONTACT_30782], who will be blinded to patient data, including the clinical condition of the patient, results of histopathology/biopsy, results of conventional imaging and PSA  levels. Patients and regions 
will be graded on a two -point scale by [CONTACT_30783] (0 = negative; 1 = positive). The 3 PET 
readers’ results will be individually compared to the SoT to generate pe r-reader performance. 
An individual PET reader will be considered successful if he/she meets the predefined thresholds for both co- primary endpoints, and at least two of three readers should be successful 
for overall study positivity. 
Regions defined for this study are prostate region (comprising prostate bed/prostate gland and 
any local invasion of the urinary bladder, rectum or seminal vesicles), PLN region, extra -PLN 
region, skeletal region and visceral region. 
The criteria to be applied for PET positivity is the following: 
[COMPANY_001]  Confidential  Page 38 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • A patient will be judged positive if at least one lesion in any region is visually positive. 
• A region will be judged as positive if at least one lesion in the region is visually positive. 
• Visually PET positive lymph nodes will be considered greater than blood pool (adjacent or 
mediastinal blood pool)  
• PET positive bone lesions will be considered greater than physiologic bone marrow 
• PET positive prostate, prostate bed and visceral lesions will be considered greater than physiologic background activity of the involvement organ or anatomic site, as previously described ( Eiber  et al 2015, Ceci  et al 2015, Fendler et  al 2019).  
Consistency of the PET  scan interpretation both between different readers and within readers is 
an important issue in medical imaging, a s it affects portability of results between institutions 
and may affect patient care.  The degree of inter - and intra -reader variability in the qualitative 
assessment of [
18F]CTT1057 PET/CT images will be assessed as a secondary endpoint to ensure 
consisten cy of interpretation and hence reliable  diagnosis, which has pi[INVESTIGATOR_30748].  
All patients will undergo 2 PET/CT scans: a [18F]CTT1057 PET/CT scan (investigational 
imaging agent) and a [68Ga]Ga -PSMA -11 PET/CT scan (as part of the CT S level 2 if required, 
and for the secondary endpoint of assessment of concordance between [18F]CTT1057 and 
[68Ga]Ga -PSMA -11 for detection of lesions) (see Section  3). The two scans will be performed 
at least 2 weeks apart for each participant in order to ensure a clean safety profile assessment 
for each PET imaging radiopharmaceutical. Moreover, in order to counter -balance any potential 
change in lesions between the 2 PET/CT scans, the PET/C T scan sequence for each patient will 
be assigned at random, in a 1:1 ratio after enrolment (see Section  6.1.4 for the definition of 
PET/CT scan sequence).  
There is preliminary evidence that PSMA PET imaging allows detection and localization of metastases in some BCR patients leading to significant changes in therapeutic approaches (Afshar -Oromieh  et al 2017). Therefore, assessment of the clinical impact of [
18F]CTT1057 
PET/CT in patient management by [CONTACT_3553] 2 questionnaires has been included as a secondary endpoint. Further details on the questionnaire are provided in Section  3. In order to reproduce 
as much as possible the real clinical context, the treating physician / Clinical Study Investigator will receive the [
18F]CTT1057 PET/CT scan report from a local nuclear medicine physician 
who will be blinded to the results of the [68Ga]Ga -PSMA -11 PET/CT scan, but will not be 
blinded to other patient data. 
In addition, the imaging diagnostic procedures included in CTS Level [ADDRESS_30151] with expertise  in reading oncology PET/CT scans as 
per SoC, who will be blinded to the  [18F]CTT1057 PET/CT scan results, but not to other patient 
data.    
. 
 See also Section  6.4 and Section  8.3 for blinding and reading details. 

[COMPANY_001]  Confidential  Page 39 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 4.2 Rationale for dose/regimen and duration of treatment  
For PET diagnostic radi opharmaceuticals, only a single administration is required, usually 
intravenously. The investigational PET radiopharmaceutical [18F]CTT1057 will be 
administered accordingly, as a single intravenous (i.v.) dose of approximately 370 MBq (range 
266– 407 MBq). This dose was shown to be safe and well tolerated in the Phase I study 
([STUDY_ID_REMOVED]), and it is in line with the recommended dose of the commercial product [18F]-
FDG according to the European Association of Nuclear Medicine (EANM) (Boellaard  et al 2015 ). Human dosimetry was studied in the Phase I  study. The effective dose 
(ED) was estimated at 0.023±0.007 millisievert (mSv)/MBq, which is in line as well with the ED of the commercial prod uct [
18F]-FDG (0.019 mSv/MBq)  according to the EANM guideline 
(Boellaard  et al 2015 ) and in other publications (0.020- 0.025 mSv/MBq) ( Kaushik et  al 2015), 
as well as the ED of other PSMA PET agents ( Behr  et al 2019) The radiation dose estimated 
from an i.v. injection of 370 MBq of  [18F]CTT1057 is 8.51 mSV. Moreover, this dose allowed 
to obtain an optimal image quality, which was rated 76 ± 5.4 on a Visual Analog Scale (VAS) of 1 to 100 (1 = non diagnostic, 100 = perfect study), by 2 experienced nuclear medicine 
physicians ( Behr  et al 2019). Further details on [
18F]CTT1057 can be found in the IB. 
The [68Ga]Ga -PSMA -11 radiopharmaceutical will be administered as a single intravenous (i.v.) 
dose of approximately [ADDRESS_30152] not be lower than 111 MBq or higher than 185 MBq in case. [
68Ga]Ga -PSMA -11 PET/CT scans will be used as part of the 
imaging component of the CTS. Refer to the [68Ga]Ga -PSMA -11 USPI  [INVESTIGATOR_30749] 
[68Ga]Ga -PSMA -11 recommendations. Refer to Section  6.7 for study drug preparation and 
dispensation. Further details on [68Ga]Ga -PSMA -11 can be found in t he IB.  
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs  
Not applicable. 
4.4 Purpose and timing of interim analyses/design adaptations  
Not applicable. 
4.5 Risks and benefits  
The use of [68Ga]Ga -PSMA -11 for PET scanning of PCa patients  has been ongoing since 2011 
to assess disease burden in the setting of primary staging (localized disease), biochemical 
recurrence (BCR; rising PSA) and advanced/metastatic disease. There are now numerous centers around the world that have clinical experi ence with [
68Ga]Ga -PSMA -11, which has been 
approved by [CONTACT_30784] ([68Ga]Ga -PSMA -11 USPI ). 
The published data consistently demonstrates that imaging with [68Ga]Ga -PSMA -[ADDRESS_30153] received [68Ga]Ga -
PSMA -11 (N=1007 ( Afshar -Oromieh  et al 2017), N=1256 ( Von Eyben et  al 2018 ), N=635 
(Fendler et al 2019), N=4149 ( Hope et  al 2019 )). These four studies have further reinforced the 
ability of [68Ga]Ga -PSMA -11 to identify PSMA -expressing PCa and demonstrate it is well 
tolerated. Recently, [68Ga]Ga -PSMA -11 has been  approved in the [LOCATION_003] (December 2020) as a 
[COMPANY_001]  Confidential  Page 40 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 radioactive dia gnostic PET imaging agent in men with PCa with suspected metastasis who are 
candidates for initial definitive therapy, or with suspected recurrence based on elevated serum 
PSA level ( [68Ga]Ga -PSMA -11 USPI ). The risk -benefit ratio is expected to be favorable to the 
[68Ga]Ga -PSMA -11 imaging agent. Further details of  [68Ga]Ga -PSMA -[ADDRESS_30154] been investigated and are under clinical 
development, all of them showing a good safety and tolerability profile. 
(Kuten  et al 2020, Szabo  et al 2015 ). The [18F]CTT1057 PET Phase -I study in 20 PCa patients 
(n=5 primary staging, n=15 mCRPC ([STUDY_ID_REMOVED]) has shown an acceptable safety profile, without any radiotracer -related adverse reactions ( Behr  et al 2019). The bio distribution  of 
[
18F]CTT1057 in humans is similar to that of other PSMA -targeted agents, and exposure rates 
of [18F]CTT1057 are also similar to those of the urea -based PET compounds, with the 
advantageous excep tion of lower exposure to kidneys and salivary glands. Preclinical and 
human dosimetry studies, and clinical experience with [18F]CTT1057  suggest good imaging 
quality properties and a favorable safety profile.  
As this is a diagnostic study patients enrolle d are not expected to derive direct benefit even 
though it is expected that distant disease will be identified in some patients as a consequence of this study and these patients may benefit from a more appropriate management plan, which will not be based on the investigational procedure alone, but confirmed by [CONTACT_30785]. 
The risk to participants in this trial may be minimized by [CONTACT_30786], as well as close clinical monitoring. Appropriate e ligibility criteria are 
included in this protocol. 
The risk -benefit ratio is expected to be favorable to the  [
18F]CTT1057  imaging 
agent. Additional details of the nonclinical and clinical experience with [18F]CTT1057  are 
provided in the IB. 
4.6 Rationale for P ublic Health Emergency mitigation procedures  
During a Public Health emergency as declared by [CONTACT_6586] i.e. pandemic, 
epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety and trial integrity are listed in rel evant sections. Notification of the Public health emergency should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by 
[CONTACT_6588].  
[ADDRESS_30155] of male participant ≥ 18 years of age, with 
biopsy proven prostate adenocarcinoma and rising PSA after definitive therapy with RP or curative-intent radiation therapy (external beam or brachytherapy), diagnosed of biochemically 
recurrent PCa.  
Approximately [ADDRESS_30156] 152 participants  are evaluable 
(i.e. have both an evaluable [
18F]CTT1057 PET/CT scan imaging,  and at least one evaluable 
[COMPANY_001]  Confidential  Page 41 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 CTS assessment and have not received any prohibited systemic antineoplastic therapy before 
the completion of PET/CTs and CTS procedures), which will be required for the calculation of the co -primary endpoints. Refer to Section  12.8.[ADDRESS_30157] meet all of the following criteria:  
1. Signed informed consent must be obtained prior to participation in the study 
2. Biopsy proven prostate adenocarcinoma. 
3a. Biochemical recurrence following initial definitive therapy (with either RP or curative intent radiation therapy) as defined:  
• by [CONTACT_30787] (Cookson et  al 2007) for patients who have undergone RP: Initial 
serum PSA of  ≥0.2 ng/ml measured at least 6 weeks after RP with a second 
confirmatory persistent PSA level of >0.2 ng/ml, or  
• by [CONTACT_30788] -Phoenix criteria ( Roach  et al 2006 ) for patients who have undergone 
curative- intent radiation therapy (RT): Rise of serum PSA measurement of 2 or more 
ng/mL above the nadir PSA observed post RT.  
4. ECOG pe rformance status [ADDRESS_30158] be adults ≥ [ADDRESS_30159]-of- care imaging 
examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)  
2. Any additional medical condition, serious intercurrent illness, concomitant cancer or other 
extenuating circumstance that, in the opi[INVESTIGATOR_689], would indicate a 
significant risk to safety or impair study participation,  including, but not limited to, current 
severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, [LOCATION_001] He art Association class III or IV congestive heart 
failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID-19 
3. Prior major surgery undergone less than 12 weeks prior to screening (with the exception 
of any surgery related to prostatic cancer)  
4. Known allergy, hypersensitivity, or intolerance to [
18F]CTT1057, [68Ga]Ga -PSMA -11, or 
to CT  contrast  
5. Prior and current use of PSMA targeted therapi[INVESTIGATOR_014]  
7a. Prior ADT (first or second generation), including LHRH analogues (agonists or   
antagonists), within 9 months before screening   
8. Any 5- alpha reductase inhibitors within 30 days before screening  
9. Use of other investigational drugs within 30 days before screening 
10. Castration -resistant patients  
[COMPANY_001]  Confidential  Page 42 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 11. Patient with small cell or neuroendocrine PCa in more than 50% of biopsy tissue  
12. Prior salvage surgery or salvage radiation therapy  
 
 
6 Treatment 
6.1 Study treatment  
The term “Study Treatment” indicates the administration of at least one of the two PET imaging 
agents: [18F]CTT1057 and [68Ga]Ga -PSMA -11 independently of whether the PET/CT  scans 
were acquired or not.  In this study, the investigational imaging agent of interest is the 
radioligand imaging compound [18F]CTT1057.  [68Ga]Ga -PSMA -11 will be used as a 
component of the CTS Leve l 2 if required, and in all participants for the secondary endpoint of 
assessment of concordance between [18F]CTT1057 and [68Ga]Ga -PSMA -11 for detection of 
lesions (as detailed in  Section  2). 
Participants will be administered both agents at least 2 weeks (14 days)  apart as an intravenous 
injection (Refer to Section  6.7 for study drug preparation and dispensation) according to the 
randomly assigned PET/CT scan sequence after enrolment.  
Participants will be administered [18F]CTT1057 and [68Ga]Ga -PSMA -11 as an intravenous 
injection, singl e dose (Refer to Section  6.7 for study drug preparation and dispensation). Both 
agents will be provided by [CONTACT_5343]. 
The general doses of the study treatment are listed in Section  6.1.  
6.1.1 Investigational and control drugs 
Table 6-1 Investigational PET imaging agents 
Investigational 
PET imaging 
agents  
(Name [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration  Supply Type  Sponsor (global or local)  
[18F]CTT1057 
370 MBq/mL at 
Calibration time 
(Tc) Radiopharmaceut
ical solution for injection   Intravenous use  Open label, vial or syringe  Sponsor (global)  
[COMPANY_001]  Confidential  Page 43 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Investigational 
PET imaging 
agents  
(Name [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration  Supply Type  Sponsor (global or local)  
[68Ga]Ga- PSMA-
11 
(150 MBq)  Either provided 
as Kit for the 
radiopharmaceutical preparation of 
[
68Ga]Ga- PSMA-
11 or as ready to 
use 
radiopharmaceuti
cal solution for 
injection   Intravenous use  Open label, vial 
or syringe  Sponsor (global)  
For background and additional details on [18F]CTT1057, refer to Section  6.7 for study drug 
preparation and dispensation and to the  [18F]CTT1057  IB. The  [18F]CTT1057 
radiopharmaceutic al will be administered intravenously at a dose of approximately 370 MBq 
(range 266 – 407 MBq). The exact dose that will have been administered to each patient will 
be recorded in the case report form (CRF) after measurement of the syringe both before and 
after administration in a dose calibrator.  
For background and additional details on [68Ga]Ga -PSMA -11, refer to Section  6.7 for study 
drug preparation and dispensation and to the  [68Ga]Ga -PSMA -11 IB. The  [68Ga]Ga -PSMA -11 
radiopharmaceutical will be administered as a single intravenous (i.v.) dose of approximately [ADDRESS_30160] been adm inistered to each patient will be recorded in the 
CRF after measurement of the syringe both before and after administration in a dose calibrator.  
6.1.2 Additional study treatments 
No other treatment beyond investigational imaging agent and the component of CTS i maging 
agent are included in this trial.  
6.1.3 Supply of study treatment  
The investigational imaging agent [
18F]CTT1057  will be provided: 
• as a single mono -dose syringe (for US) or a single multidose vial (for European Union 
(EU)) ready to use radiopharmaceutical  solution for injection, with a volumetric activity 
of 370 (±10%) MBq/mL  at the reference date and time (calibration time (Tc)).  
The natural decay of the radionuclide leads to a continuous decrease of the specific activity, the 
total radioactivity and the radioactive concentration (volumetric activity) over the time. Therefore  the volume of the solution injected varies in order to provide the required amount of 
radioactivity at the date and time of injection. The exact expi[INVESTIGATOR_30750] [
18F]CTT1057 certificate of release as 
described in the Pharmacy Manual. .  
The component of CTS imaging agent [68Ga]Ga -PSMA -11 will be provided: 
[COMPANY_001]  Confidential  Page 44 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • as a kit for radiopharmaceutical preparation: single vial with a white lyophilized powder to 
be locally reconstituted with  a solution of gallium-68 chloride (68GaCl 3) in HCl eluted 
from an approved 68Ge/68Ga generator (for the clinical sites equipped with an 
approved 68Ge/68Ga generator).   
• as a single dose r eady to use radiopharmaceutical solution: vial or syringe with the 
radiopharmaceutical solution supplied by [CONTACT_30789] (for the clinical sites not equipped with an approved 
68Ge/68Ga generator).   
The volume of  [68Ga]Ga -PSMA -11 solution for injection, corresponding to the radioactive dose 
to be administered, is calculated according to the estimated time of injection, on the basis of the current activity provided by [CONTACT_30790] (half -life = 
68 min). A fter reconstitution, the  [
68Ga]Ga -PSMA -[ADDRESS_30161] be handled and administered by [CONTACT_3784]/authorized personnel only and 
must be prepared in accordance with pharmaceutical quality requirements and radiation safety 
regulations. 
6.1.4 Treatment arms/group 
This is a single- arm study. However, the PET/CT scan sequences for each participant will be 
assigned at random in a 1:1 ratio after enrolment:  
• Sequence 1: [18F]CTT1057 (investigational imaging agent of interest) followed by 
[68Ga]Ga -PSMA -11 (as part of CTS [if required] and for secondary endpoint). 
• Sequence 2: [68Ga]Ga -PSMA -11 (as part of CTS [if required] and for secondary endpoint) 
followed by [18F]CTT1057 (investigational imaging agent of interest).  
Please refer to Section  6.3.2 for assignment details.  
6.1.5 Treatment duration 
The planned duration of treatment period (i.e. single -dose administration of the 2 PET  imaging 
agents) is at least  [ADDRESS_30162] administered imaging agent or at the discretion of the investigator or the participant. 
Upon end of treatment and the study, participants may be treated with any other medications per discretion of the treating physician.  
6.2 Other treatment(s)  
6.2.1 Concomitant therapy 
All medications, procedures, and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and 
blood transfusions) administered after the participant  was enrolled into the study must be 
recorded on the appropriate Case Report Forms. 
[COMPANY_001]  Confidential  Page 45 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Each concomitant drug must be individually assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_30791] a participant or allowing a new medication to be started. If the participant is already enrolled, contact [CONTACT_30792]. 
Use of diuretics (e.g. furosemide) to help subject to void before PET/CT scan imaging 
acquisition is allowed in case of need, upon the discretion of the investigator. 
 
6.2.2 Prohibited medication 
Any medication, therapy or procedure (other than the study treatment) that may interfere with 
PSMA PET i maging is not allowed. Prior to completing both PET  imaging scans and CTS 
procedures, any ADT including LHRH analogues (agonists or antagonists) as well as anti -
androgens (both first and second generation compounds) and 5- alpha reductase inhibitors are 
prohibited. Any therapy/procedure  that could interfere with PET PSMA imaging is not allowed.  
6.3 Participant numbering, treatment assignment, randomization  
6.3.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is assigned when the participant is enrolled for screening and is retained for the participant throughout his participation in the trial. A new Participant No. will be assigned at every subsequent enrollment if the participant is re -screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential participant number suffixed to it, so that each participant’s participation is numbered uniquely across the entire database. Upon  signing the informed consent form, the participant is assigned 
to the next sequential Participant No. available. 
A new ICF will need to be signed if the investigator chooses to re -screen the participant after a 
participant has screen failed, and the participant will be assigned a new Participant No.  
6.3.2 Treatment assignment, randomization  
The IRT will be used to assign the PET/CT scan sequence to each eligible participants at random 
(1:1 ratio), and the randomization numbers will be stored in IRT. The investig ator or his/her 
delegate will contact [CONTACT_6608]/exclusion criteria.  
The investigator or his/her delegate will order [
18F]CTT1057  or [68Ga]Ga -PSMA -11  dose  
prior to the scheduled dosing date (r efer to Pharmacy Manual). Each administration will be 
tracked by [CONTACT_30793]/her delegate via IRT. Detailed instructions of Investigational 
Medicinal Product (IMP) ordering and IRT use will be provided in the Pharmacy Manual. 
[COMPANY_001]  Confidential  Page 46 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 6.4 Treatment blinding  
Treatment and PET/CT scan sequence assignment will be open to participants, investigator 
staff, persons performing the assessments, and the study team. The following blinding is applicable in this study: 
• [
18F]CTT1057 PET/CT images will be submitted to a C RO for independent centralized 
read by 3 independent readers blinded to patient data collected in clinical database (such 
as medical history details or diagnostic test results).  
• In addition, [18F]CTT1057 PET/CT images will be read by [CONTACT_30794]/CT scans at each site, who will be blinded to [
68Ga]Ga -PSMA -11 PET/CT imaging results, but not to other 
patient data. The results will be shared with the treating physician / Clinical Study Investigator to support the completion of the patient management questionnaire 2.  
• Images from diagnostic procedures included in the CTS  Level 2 will be submitted to a 
CRO for independent centralized read by [CONTACT_30795], blinded to [
18F]CTT1057 
PET/ CT images, but not to other patient data collected in clinical database.  
• In addition, these CTS images will be read by a local nuclear medicine physician or radiologist with expertise in reading oncology PET/CT scans at each site as per SoC, who will be blinded to [
18F]CTT1057 PET/CT imaging results, but not to other patient data. 
• In the cases wh ere pathology will be available, assessments by [CONTACT_30796]. Pathologists will be blinded to any PSMA-PET data (i.e. both PET/CT scans).  
6.5 Dose escalation and dose modification  
Investigational or other study treatment dose adjustments and/or interruptions are not applicable in this study in which each imaging agent is administered only once. 
6.5.[ADDRESS_30163] once a week (or more frequently if required by [CONTACT_15931], or if clinically indicated) for [ADDRESS_30164] be recorded in the Drug Accountability Log and 
in the corresponding electronic case report form (eCRF) pages.  

[COMPANY_001]  Confidential  Page 47 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 6.7 Preparation and dispensation  
Each study site will be supplied with study investigational imaging agent in packaging as 
described under investigational and control drugs Section  6.1.1. 
For [18F]CTT1057 and [68Ga]Ga -PSMA -11 preparation and administration, please refer to 
procedure and instructions contained in the Pharmacy Manual. 
Investigator staff will know the study treatments to dispense to the participant by [CONTACT_30797] (between Day - 28 and Day -14). 
For [18F]CTT105 7 and [68Ga]Ga -PSMA -[ADDRESS_30165] be stored according to the instructions specified in the IB.  
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective [COMPANY_001]  Country Organization (CO) Quality Assurance. 
The investigator must maintain an accurate recor d of the shipment and dispensing of study 
treatments in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_30798].  
[
18F]CTT1057  
The packaging [18F]CTT1057 consists in a white glass multidose vial (For EU) or a monodose 
syringe (US) containing the sterile radioactive solution.  
[18F]CTT1057 solution should be handled by [CONTACT_30799] a manner which satisfies both radiation 
safety and pharmaceutical quality requir ements. Appropriate aseptic precautions should be 
taken, complying with the requirements of Good Manufacturing Practice for pharmaceuticals. Since [
18F]CTT1057 is a ready- to-use solution, no manipulation of the investigational imaging 
agent is intended at the clinical site,  except the:  
• dispensation into monodose syringes, or the use of automatic dispenser and infusion 
system, according to local procedure, when applicable.  
• disposal which must be documented appropriately and a copy of the completed drug accountability log should be sent on a regular basis to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator folder at each site.  
[COMPANY_001]  Confidential  Page 48 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 The radioactive [18F]CTT1057 will be locally discarded according to all disposal requirements 
and local regulations for radioactive materials.  
For [18F]CTT1057 solution storage conditions, quality control (QC), administration and 
disposal, clinical sites must follow instruction as describe in the [18F]CTT1057 Pharmacy 
Manual.  
These different steps in [18F]CTT1057 product management have to be documented as 
described in the Phamacy Manual using forms/log provided in the investigator folder at each 
site in order to ensure traceability of the product at any time.  
[18F]CTT1057 labels will be in the local language and comply with the legal requirements of 
each country. They will include storage conditions, batch no, expi[INVESTIGATOR_5695]. 
[68Ga]Ga-PSMA -11 
The packaging of PSMA -11 kit consists of a box (secondary packaging) and one 10 mL glass 
vials (primary packaging). 
[68Ga]Ga -PSMA -11 will be supplied by [CONTACT_30800] a sterile, one -vial kit for reconstitution with 
68Ga solution eluted from approved commercial Good Manufacturing Practice (GMP) 
68Ge/68Ga generator to:  
1. the clinical site, in case of the kit’s reconstitution and radiolabelling will be performed at 
hospi[INVESTIGATOR_307]’s radiopharmacy, 
2. the radiopharmacy appointed by [CONTACT_456], in case of an external radiopharmacy will be in charge of the kit’s reconstitution and radiolabeling.  
In the second case, the clinical site will order the [
68Ga]Ga -PSMA -11 single dose ready to use 
solution for injection following the instructions described in the Pharmacy manual.  
[68Ga]Ga -PSMA -[ADDRESS_30166] be prepared and administered at the investigational site by 
[CONTACT_30801]. The instruction for radiolabeling procedure and dispensing [
68Ga]Ga -PSMA -11, cautionary notes, analytical controls and stability of the radiolabeled 
product will be provided to each site (please refer to the Pharmacy Manual). 
After reconstitution with  68Ga solution eluted from GMP 68Ge/68Ga generator, the imaging 
agent is a radioactive substance which must be stored, handled and administered by 
[CONTACT_3784]/authorized personnel only as described in the Pharmacy Manual and must be prepared in accordance with pharmaceutical quality requirements and radiation safety regulations.  
The kit for the preparation of [
68Ga]Ga -PSMA -11 should be stored upon receipt according to 
storage conditions as described in the medication label.  
The imaging agent [68Ga]Ga -PSMA -11 will be locally discarded according to all disposal 
requirements and local regulations for radioactive materials. The disposal of all study treatment will be documented appropriately  and a  copy of the completed drug accountability log should 
be sent on a regular basis  to the  [COMPANY_001] monitor or to the  [COMPANY_001]  address provided in the 
investigator folder at each site.  
Kits labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions, batch number, expi[INVESTIGATOR_5695].  
[COMPANY_001]  Confidential  Page 49 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 [68Ga]Ga -PSMA -11 ready to use radioactive solution labels will be in the local language and 
comply with the legal requirements of each country. They will include storage conditions, batch 
no and expi[INVESTIGATOR_5695].  
6.7.2 Instruction for preparing and administering study treatment  
[18F]CTT1057  
Preparation  
[18F]CTT1057 is a ready- to-use multi- dose vial (EU) or a mono -dose syringe (US).  
The instruction for cautionary notes, analytical controls and stability of the radiolabeled product will be provided to each site (please refer to the Pharmacy Manual).  
Administration  
Injection of  [
18F]CTT1057 must be performed in accordance with national and/or local 
radiation and safety requirements.  
[18F]CTT1057 will be injected intravenously at approximately 370 MBq (range 266 – 407 
MBq), then flushed by [ADDRESS_30167] be used, handled and 
administered by [CONTACT_3784]/authorized personnel only and must be prepared in accordance with the Pharmacy Manual,  pharmaceutical quality requirements and radiation safety 
regulations. 
The total activity administered must be recorded  (mCi or MBq) by [CONTACT_30802] 
(or activimeter).  
For clinical sites equipped with an automatic infusion system, apply the local procedure to register the exact amount of radioactivity injected.  
[
68Ga]Ga -PSMA -11 
Preparation  
In case of the kit’s reconst itution and radiolabelling will be performed at hospi[INVESTIGATOR_307]’s 
radiopharmacy. 
The instruction for radiolabeling procedure, cautionary notes, analytical controls and stability 
of the radiolabeled product will be provided to each site (please refer to the Pharma cy Manual).  
In case of an external radiopharmacy will be in charge of the kit’s reconstitution and radiolabeling, the clinical site will receive the [
68Ga]Ga -PSMA -11 single dose ready to use 
solution for injection.  
Administration  
[68Ga]Ga -PSMA -[ADDRESS_30168] be administered at the dose as presented in Section  6.1.1  
investigational site by [CONTACT_30801]. The instruction for radiolabeling procedure and dispens ing [
68Ga]Ga -PSMA -11, cautionary notes, analytical controls and 
[COMPANY_001]  Confidential  Page 50 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 stability of the radiolabeled product will be provided to each site (please refer to the Pharmacy 
Manual).  
After reconstitution with  68Ga solution eluted from GMP  68Ge/68Ga generator, the 
investigational product is a radioactive substance which must be used, handled and administered 
by [CONTACT_3784]/authorized personnel only and must be prepared in accordance with the Pharmacy Manual, pharmaceutical quality requirements and radiation safety regulat ions.  The total activity 
administered must be recorded  (GBq, Millicurie (mCi) or MBq) by [CONTACT_30802] (or activimeter).  
7 Informed consent procedur es 
Eligible participants may only be included in the study after providing (witnessed, where required by [CONTACT_6617]), Institutional Review Board (IRB)/Independent Ethics Committee (IEC)- approved informed consent.  
If applicable, in cases where the participant's representative(s) gives consent (if allowed according to local requirements), the participant must be informed about the study to the extent 
possible given his understanding. If the participant  is capable of doing so, he/she must indicate 
agree ment by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent  must be 
documented in the participant source documents.  
As per Section  4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_30751], that may challenge the ability to obtain 
a standard written informed consent due to limits that prevent an on- site visit, the Investigator 
may conduct the informed consent discussion remotely (e.g. telephone, videoconference), if allowable by a local Heath Authority. Guidance issued by [CONTACT_6621] (e.g. the presence of an impartial witness, sign/dating separate ICFs by [CONTACT_6622], etc.). 
[COMPANY_001]  will provide to investigators in a separate document a proposed informed consent form 
that complies with the International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) E6 Good Clin ical Practice (GCP) guidelines and 
regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_30804]/IEC.  
Information about c ommon side effects already known about the investigational drug can be 
found in the IB. This information will be included in the participant  informed consent and 
should be discussed with the participant  during the study as needed. Any new information 
regar ding the safety profile of the investigational drug that is identified between IB updates will 
be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an update to the info rmed consent and then must 
be discussed with the participant. 
[COMPANY_001]  Confidential  Page 51 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 The following informed consents are included in this study: 
• Main study consent, which also includes:  
• a subsection that requires a separate signature [CONTACT_30833] ‘Optional Consent 
for Additional Research’ to allow future research on data/samples collected during this study. 
A copy of the approved version of all consent forms must be provided to [COMPANY_001]  after IRB/IEC 
approval. 
[ADDRESS_30169] be supported in the participant’s source documentation. 
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
Table 8-1 or as close to the designated day/time as possible. Missed or rescheduled visits should 
not lead to automatic dis conti nuation. Participants who discontinue from the study treat ment 
are to return for the end of treatment visit as soon as possible, and attend the follow -up visits as 
indicated in the Assessment Schedule. Participants who discontinue from study or withdraw their consent/oppose the use of their data/biological samples should be scheduled for a final 
evaluation visit if they agree, as soon as possible, at which time all of the assessments listed for the final visit will be performed. At this final visit, all administered imaging agents should be reconciled, and the adverse event and concomitant medications not previously reported must be recorded on the CRF. 
As per Section  4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on -site study visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_30805]. If allowed by [CONTACT_30806], phone calls, virtual contacts (e.g. tele consult) or visits by [CONTACT_6624]/ home nursing staff to the participant´s home, can replace on -site study visits, for the duration of the disruption 
until it is safe for the participant to visit the site again.  
[COMPANY_001]  Confidential  Page 52 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Table 8-1 Assessment Schedule 
Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30170] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
Informe
d 
Consent  X                                 
IRT Participant 
Registra
tion X                                 
Inclusio
n / 
Exclusio
n 
Criteria  X                                 
Medical History 
& 
Demogr
aphics  X                                 
[COMPANY_001]  Confidential  Page 53 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30171] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
Electroc
ardiogram 
(ECG)  X                                 
ECOG Perform
ance 
Status  X                                 
Physical 
Examina
tion S (short)   S 
(short)            S 
(short)            S 
(short
)     
Body 
Weight X   X           X                 
Body 
Height  X                                 
Vital 
Signs4 X   X   X   X   X   X   X   X     
Hematol
ogy5 X   X           X           X     
Clinical Chemist
ry X   
X           
X           
X     
[COMPANY_001]  Confidential  Page 54 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30172] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
PSA 
level X                             X (Prior RT 
and [ADDRESS_30173] 
RT)   
Urinalysi
s6 S   S           S           S     
IRT 
Random
ization    
X                               
[18F]CTT
1057 
and 
[68Ga]G
a-PSMA-
11 
Ordering
7   
X                               
Adverse 
Events   
AEs to be collected throughout this period      
[COMPANY_001]  Confidential  Page 55 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30174] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
[18F]CTT
1057 / 
[68Ga]G
a-PSMA-
11 or 
[
68Ga]G
a-PSMA-
11 / 
[
18F]CTT
[ADDRESS_30175]
ration8       
X           
X               
Concomitant 
Medicati
ons Concomitant Medications to be collected throughout this period      
[COMPANY_001]  Confidential  Page 56 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30176] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
[18F]CTT
1057 
/[68Ga]G
a-PSMA-
11 
PET/CT 
Imaging
9           
X           
X           
Patient 
Management 
Questio
nnaire  Before and within 14 days after [18F]CTT1057 PET/CT scan results      
Histopat
hology, 
if 
applicab
le  
    
If indicated, biopsy/salvage 
surgery should be performed 
within 8 weeks after completion 
of the  [18F]CTT1057 PET/CT 
scan AND after completion of 
the   [68Ga]Ga -PSMA-11 
PET/CT scan  
[COMPANY_001]  Confidential  Page 57 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30177] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30178] (or MRI if CT scan with contrast is  medically contraindicated), and any other SoC imaging 
diagnostic procedure as clinically indicated per SoC (CT/MRI, Bone Scan, etc.), performed within 8 weeks before or after [18F]CTT1057 scan  
Safety Follow 
up Call                
X           
X     
X 
End of Phase Dispositi
on X           
X           
X       
X 
* All Screening assessments to confirm eligibility into the study must be performed prior randomization.  
X Assessment to be recorded in the clinical database or received electronically from a vendor  
S Assessment to be recorded in the source documentation only  
1 Participants will undergo either [68Ga]Ga -PSMA-11 PET/CT followed by [18F]CTT1057 PET/CT at least 14 days apart, or [18F]CTT1057 PET/CT followed by [68Ga]Ga -
PSMA-11 PET/CT at least 14 days apart  
2   Additional follow -up includes any SoC pathology assessment (of a biopsy/salvage surgery performed up to 8 weeks from [18F]CTT1057 PET/CT scan, CTS level 1) 
and/or any SoC imaging diagnostic procedures assessments (at least a high-resolution CT with contrast)  performed up to 8 weeks from [18F]CTT1057 PET/CT scan for 
CTS level 2; If CTS level 3 is applicable for the participant (in case Levels 1 or 2 are not feasible, inconclusive or negati ve), the PSA levels will be assessed prior to RT, 
[COMPANY_001]  Confidential  Page 58 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No.  CAAA405A12301  
 
 
 Period  Screening*  Treatment  Additional 
Follow -up Study 
Completion  
Visit 
Name  [CONTACT_30834] 11 Safe
ty 
Che
ck 1 PET Imaging 21 Safet
y 
Chec
k 2 Safet
y 
Follo
w-up Additional 
Follow -
up2 EOS 
Days  Day -28 
to Day -
14 Day –28 
to Day -
14  Day 1  
(+7) Day 
2 to 
3 Day 15 (+7)  Day 
16 to 
17 Day 
29 (+ 
3) up to 90 
days after 
RT Day 29 to 
Follow -up 
end 
Time 
(post -
dose)  - - Pre-
Injecti
on Inje
ctio
n Post -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT [ADDRESS_30179] -
Injection/ 
Pre-Imaging  Ima
gin
g Post -
Imaging / 
EOT 2  - - - - 
which should commence within 8 weeks after [18F]CTT1057  PET/CT scan and after both PET/CTs are completed, and at approx. [ADDRESS_30180] PET Imaging Day  
4 Vital signs wi ll be performed at screening, at Imaging days (pre and post -injection and then before patient discharge) and at Safety follow -up visit (Day29)  
5 Peripheral venous blood samples will be collected at screening, PET Imaging Days pre -injection and at Safety follow- up (Day 29)  
[ADDRESS_30181] period from order to delivery  
8 Participant will be injected intravenously either approximately 370 MBq (range 266 –407 MBq) of [18F]CTT1057 or approximately 150 MBq (range 111-185MBq) of 
[68Ga]Ga -PSMA-11, flushed with 10 mL saline  
9after [18F]CTT1 [ADDRESS_30182] will be obtained from vertex to mid-thighs, followed by [CONTACT_30807] -thighs. 50-100 min after [68Ga]Ga -PSMA-[ADDRESS_30183] will be obtained from vertex to mid-thighs, followed by [CONTACT_30808]-thighs.   
 

[COMPANY_001]  Confidential  Page 59 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 8.[ADDRESS_30184] be registered in IRT, eligibility reviewed and, once eligible, study treatment ordered. 
Laboratory assessments should be carried out as priority to allow the necessary time to obtain 
the resu lts and to confirm participant eligibility prior to randomization and study treatment 
ordering in IRT. All Screening assessments to confirm eligibility into the study should be performed between Day -28 and Day - 14 as per Visit Assessment Schedule in Table 8 -1. 
It is permissible to re -screen (only once)  a participant if he fails the initial screening (screen 
failure); however, each case must be discussed and agreed with the Sponsor on a ca se-by- case 
basis. Re- screening should not performed for avoiding the eligibility criteria, putting the 
participant at safety risk. Re- screened participants will need to be re- consented and a new 
Participant Number will be assigned. Re -screening tests should be repeated as per 
inclusion/exclusion requirements and re -screening should be documented in medical records.  
8.1.1 Eligibility screening  
Following registering in the IRT for screening, participant eligibility will be checked once all screening procedures are  completed. The eligibility check will be embedded in the IRT system. 
Please refer and comply with detailed guidelines in the IRT manual.  
8.1.2 Information to be collected on screening failures  
Participants who sign an informed consent form and subsequently found to be ineligible prior to randomization will be considered a screen failure. The reason for screen failure should be recorded on the appropriate Case Report Form. The demographic information, informed consent, and Inclusion/Exclusion pages must also be c ompleted for screen failure participants. 
No other data will be entered into the clinical database for participants who are screen failures, unless the participant experienced a serious adverse event during the screening phase (see SAE section for reporting details). If the participant fails to be randomized, the IRT must be notified within 2 days of the screen fail that the participant was not randomized. 
Participants who are randomized and fail to start treatment, e.g. participants randomized in 
error, will be considered an early terminator. The reason for early termination should be 
recorded on the appropriate Case Report Form. 
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.  
[COMPANY_001]  Confidential  Page 60 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Participant demographic and baseline characteristic data are to be collected on all participants. 
Participant race and ethnicity are collected and analyzed to identify variations in safety or efficacy due to these factors as well as to assess the diversity of the study population as required by [CONTACT_6628]. 
Relevant medical history/current medical condition present before signing the informed consent 
will be recorded. Investigators will have the discretion to record abnormal test findings on the appropriate eCRF whenever in their judgment, the test abnormality occurred prior to the informed consent signature. 
Participant demographic and baseline characteristic data to be assessed  on all subjects include: 
• Demographic information: age, gender, self- identified race and ethnicity  
• Vital signs: body temperature, blood pressure, heart rate (HR), respi[INVESTIGATOR_697] (RR),  
• Weight and height  
• ECOG Performance status scale  
• 12 Lead ECG 
• Laboratory  evaluations: hematology, chemistry, urinalysis test and PSA (see 
Section  8.4.1).  
Participant medical history to be documented in eCRF include:  
• Date of diagnosis of PCa  
• Gleason grade at diagnosis, PSA at diagnosis, Clinical stage (cTNM) at diagnosis  
• In patients with RP or patients with RT: PSA at diagnosis, gleason score of the RP 
specimen, pathological stage (pTNM) at diagnosis, information on additional salvage RT (prostate bed, lymphatic drainage), PSA nadir, first PSA >2ng/ml.   
• PSA nadir after RT (if applicable)  
• Ongoing medical conditions, symptoms and diseases which are recorded on the Medical History eCRF should include the toxicity grade when applicable 
• Concomitant medications of the last 30 days prior to enrollment (dose, dates) 
• Other important medical, surgical, and allergic conditions that could have an impact on the participant's evaluation) / current medical conditions (e.g. all relevant current medical conditions which are pr esent at the time of signing informed consent).  
8.3 Efficacy  
Efficacy assessments in this study include disease assessment per SoC at baseline (and if clinically indicated, post -baseline) as well as assessments of PET/CT  images using the two 
PET agents. Please refer to the schedule of assessments provided in Table 8 -1 and Section  8.3.1. 
8.3.1 Imaging for tumor assessment  
The imaging assessment collection plan for this study is presented in Table 8 -2. 
[COMPANY_001]  Confidential  Page 61 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Table 8-2 Imaging Assessment Collection Plan  
 
 Imaging procedures  Mandatory or Optional  Image Acquisition Timing  
[18F]CTT1057 PET/CT  Mandatory - all 
participants Day 1 or Day 15* 
[68Ga]Ga -PSMA -11 PET/CT Mandatory - all 
participants Day 1 or Day 15* 
High Resolution CT with i.v. 
and Oral Contrast (or MRI if CT scan with contrast is medically contraindicated) of 
at least Chest Abdomen and Pelvis (and any additional 
region as clinically indicated)  Mandatory - all participants  +/- 8 weeks from 
[
18F]CTT1057 PET/CT 
Acquisition 
Other Standard of Care 
Imaging diagnostic procedures 
(MRI, Bone Scan, PET with 
other imaging agents, etc.)  As clinically indicated per SoC  +/- 8 weeks from 
[
18F]CTT1057 PET/CT 
Acquisition 
Follow- up Standard of Care 
Imaging d iagnostic procedures 
(CT, MRI, Bone Scan, PET 
with other imaging agents, etc.)  If clinically required per SoC for the diagnosis of particular lesion(s)  3 months after the initial imaging procedure performed  
*Day 1 or 15 de termined by [CONTACT_3445]’s randomization into sequence 1 or 2.  
Imaging diagnostic procedures (CT/MRI, bone scan, or other modalities) should be performed as clinically indicated for each patient per SoC within 8 weeks (either before or after) the [
18F]CTT1057 PET/CT scan. Any imaging assessments already completed during the regular 
work -up of the participant within 8 weeks prior to [18F]CTT1057 PET/CT scan, including 
before signing the main study ICF, can be considered as part of imaging component of the CTS Level 2. 
CTS Level [ADDRESS_30185] (or MRI if C T scan with contrast is medically contraindicated) and 
the [
68Ga]Ga -PSMA -11 PET/CT scan. It may include also any other imaging diagnostic 
procedures clinically indicated for each participant as per SoC (including three -month follow -
up imaging where it is clinically required for the diagnosis of particular lesion(s)). A centralized 
reading of these imaging diagnostic procedures will be performed in a CRO by 3 readers who will be blinded to [
18F]CTT1057 PET/CT scan results, but not to other patient data collected in 
[COMPANY_001]  Confidential  Page 62 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 clinical database. The majority rule (2/3 readers) will be used as a final outcome of the reads. 
Further details will be provided in the Imaging Charter.  
In addition, the imaging diagnostic procedures included in CTS level 2 will be read by [CONTACT_30809]/CT scans as per SoC, who will be blinded to the  [
18F]CTT1057 PET/CT scan results, but not to other 
patient data.    
 The criteria to be 
applied for PET positivity are detailed in Section 4.1. 
SoC imaging data to be documented in eCRF will include the outcome of assessmen ts, i.e. if 
negative or positive for PCa tumor or metastases, regions where lesions are identified, number 
and location of the lesions. For lesions that are visually positive on the [
68Ga]Ga -PSMA -11 PET 
but not considered as PCa, their characteristics will  be documented (i.e. non- prostate cancer 
tumoral or benign, such as inflammatory, degenerative, necrotic, other). For CT/MRI lesion size measurements RECIST 1.1 guidelines will be applicable ( Section  16.2).  
Post-baseline PET imaging assessments  
PET imaging assessments as described in Table [ADDRESS_30186] on each PET imaging day: 
[
68Ga]Ga -PSMA -11 PET imaging day (as part of the imaging component of CTS):  
1. Participant will be asked to drink 1 -2 glasses of water before arrival at the clinic  
2. Participants will be weighed and vital signs (body temperature, blood pressure, heart rate, 
respi[INVESTIGATOR_697]) will be recorded prior injection.  
3. Participant will be injected i.v. with a single dose of approximately 150 MBq of [
68Ga]Ga‑PSMA‑11, administered doses must not be lower than 111MBq or higher than 
185MBq in any case then flushed by 10 ml of saline. For [18F]CTT1057 administration, 
please see below  
4. Vital signs (body temperature, blood pressure, heart rate, respi[INVESTIGATOR_697]) will be recorded 
after the injection  
5. Participant will void immediately prior to the scan. If it is not possible for the patient to 
void, an urethral catheterization will be considered 
6. Approximately 50 to  100 minutes (min) later, a CT (transmission scan) will be obtained 
from vertex to midthighs for anatomical reference and attenuation correction purposes. This will be followed by a static PET emission scan over the same area, starting from mid thighs Refer to imaging charter and/or site imaging manual for details 
7. If intense activity in the urinary bladder is seen in the PET/CT images that precludes 
appropriate assessment of the prostate bed and/or PLN regions, then the participant will be 
allowed to void again, and uretheral catheterization and a new (1 bed) PET/CT image of the pelvis will be considered in case of need. T his additional pelvic image can then be 
acquired within approximately 120+[ADDRESS_30187]- injection (p.i.)  

[COMPANY_001]  Confidential  Page 63 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 8. Vital signs (body temperature, blood pressure, heart rate, respi[INVESTIGATOR_697]) will be recorded 
again at the completion of the study (prior to participant discharge)  
9. Participant will be discharged with the reminder of the safety follow up as described in the Informed Consent Form (ICF).  
[
18F]CTT1057 (investigational imaging agent) PET imaging day:  
1. Participant will be asked to drink 1 -2 glasses of  water before arrival at the clinic  
2. Participants will be weighed and vital signs (body temperature, blood pressure, heart rate, respi[INVESTIGATOR_697]) will be recorded prior injection.  
3. Participant will be injected i.v. with approximately 370 MBq (range 266 – 407 MBq) of [
18F]CTT1057, flushed by 10 ml of saline 
4. Vital signs (body temperature, blood pressure, heart rate, respi[INVESTIGATOR_697]) will be recorded after the injection  
5. Participant will void immediately prior to the scan. If it is not possible for the patient to 
void, a urethral catheterization will be considered.  
6. [
18F]CTT1057 PET/CT scan acquisition will preferably, 
 
 A CT 
(transmis
sion scan) will be obtained from vertex to midthighs for anatomical reference 
and attenuation correction purposes. This will be followed by a static PET emission scan over the same area, starting from  mid thighs  Refer to imaging charter and/or site imaging 
manual for details  
7. If intense activity in the urinary bladder is seen in the PET/CT  images that precludes 
appropriate assessment of the prostate bed and/or PLN regions, then the participant will be asked to void again, and uretheral catheterization and a new (1 bed) PET/CT image of the pelvis will be considered in case of need. This additional pelvic image can then be acquired within approximately 
8. Vit
al signs (body temperature, blood pressure, heart rate, respi[INVESTIGATOR_697]) will be recorded 
again at the completion of the study (prior to participant discharge)  
9. Participant will be discharged with the reminder of the safety follow up as described in the 
Informed Consent Form (ICF).  
PET/CT imaging data to be documented in eCRF will include the outcome of the assessment, 
i.e. if negative or positive for PCa tumor or metastases, regions where lesions are identified, 
number and location of the lesions as well as their characteristics.  
[18F]CTT1 057 PET/CT images will be submitted to the designated imaging CRO for 
independent central review. All reviewers have to be blinded to patient data (including clinical condition, histopathology and imaging results). Central read results will not be provided to the 
treating physician/Clinical Study Investigator.  
[
18F]CTT1057  PET/CT images will also be read by [CONTACT_30810]/CT scans, blinded to [68Ga]Ga -
PSMA -11 PET/CT scan r esults, but not to other patient data.  The report from this local reader 

[COMPANY_001]  Confidential  Page 64 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 will be provided to the treating physician / Clinical Study Investigator to complete the patient 
management questionnaire 2. 
[68Ga]Ga -PSMA -11 PET/CT images will be both centrally and locally read as all the other 
imaging procedures included in CTS Level 2.  
8.3.2 Histopathology assessments  
In the cases where pathology will be available (from prospective biopsy or salvage 
surgery  performed within 8 weeks after the completion of [18F]CTT1057 PET/CT scan and 
after the completion of  [68Ga]Ga -PSMA -11 PET/CT scan), assessments by [CONTACT_30811], and results are to be provided within 2 weeks of the biopsy. Pathologists will be blinded to any PSMA -PET data (i.e.  both PET/CT scans), but not 
to other patient data. 
Pathology data to be documented in eCRF will include among others the 
procedure/methodology used, the outcome of the assessment, i.e. if negative or positive for adenocarcinoma, if other tumor histological types are present or not and their nature, number, location as well as size of the tumor and/or metastatic lesions within the tissue specimens.   
8.3.3 PSA level assessments 
For CTS Level 3, increases and decreases of PSA  levels will be tracked to assess PSA r esponses 
before and after RT (third component of the CTS) as per PCWG3 for participants where 
pathology or radiological assessments are not available or conclusive.  
RT should commence within approximately 8 weeks of completing the study treatment (i.e. both PET/CT scans) and PSA should be assessed prior to starting the RT  and then at 
approximately [ADDRESS_30188] day of radiation.  
8.3.4 Appropriateness of efficacy assessments  
[
18F]CTT1057 PET/CT efficacy assessments will be based on a Composite Truth Standard 
(CTS), as described in Section  3 (in brief: CTS  Level 1=pathology, CTS  Level 2= imaging 
diagnostic procedures, CTS Level 3= PSA changes). See Section  1.[ADDRESS_30189]/MRI lesion size measurements, applicable RECIST v1.1 guidelines Section  16.2 will 
be used. For PSA measurements after RT (third component of the CTS) PCWG3 guidelines 
Section  16.3  will apply. PCWG3 is an international working group of clinical and translational 
experts in PCa who developed international recognized recommendations.  
8.4 Safety  
Safety assessments are specified below ( Table 8 -3) with the assessment schedule detailing when 
each assessment is to be performed. For participants undergoing surgery prior to planned safety visit, these safety follow -up assessments will need to be performed before the surgery. 
As per Section  4.6, duri
 ng a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on -site study visits, 
[COMPANY_001]  Confidential  Page 65 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 regular phone or virtual calls will occur (as close as possible to the visits as per schedule) for 
safety monitoring and discussion of the participant´s health status until it is safe for the participant to visit the site again. If participants cannot visit the site for protocol specified safety lab assessments, an alternative lab (local) collection site may be used.   
For details on AE collection and reporting, refer to AE section.  
[COMPANY_001]  Confidential  Page 66 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Table 8-[ADDRESS_30190] be recorded as 
an adverse event.  
Vital signs  Vital signs include Systolic Blood Pressure (SBP) and Diastolic Blood 
Pressure (DBP) (supi[INVESTIGATOR_30752]), HR, RR 
and body temperature.  
Weight and Height  Body weight (in indoor clothing, but without shoes) and height will be 
measured as specified in Table 8 -1. 
Performance status:  
ECOG Performance status scale will be used as described below ( Table 8 -4). 
Table 8-4 Performance Status 
Score  Performance Status  
0 Fully active, able to carry on all pre disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, light housework, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up 
and about more than 50% of waking hours  
3 Capable of  only limited self -care, confined to bed or chair more than 50% of waking 
hours  
[ADDRESS_30191] be evaluated for criteria defining an adverse event and reported 
as such if the criteria are met. For those lab adverse events, repeated evaluations are mandatory 
until normalization of the result(s) or until the result is no longer considered to be clinically significant.  
[COMPANY_001]  Confidential  Page 67 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria: 1) th ey induce clinical signs or symptoms, 2) they are considered 
clinically significant, or 3) they require concomitant therapy or procedures. Clinically significant abnormal laboratory values or test results should be identified through a review of values out side of normal ranges/clinically notable ranges, significant changes from screening 
or the previous visit. 
Unscheduled local laboratory assessments may be performed if medically indicated to assess a 
(potential) adverse event or when the treating physician cannot wait for central laboratory 
results for decision making (e.g. therapeutic intervention, interruption of study treatment). In this particular situation, if possible, the blood sample obtained at the same time point should be submitted to the central  laboratory for analysis in parallel with local analysis. The results of the 
local laboratory will be recorded in the eCRF if any of the following criteria are met:  
• Local lab results document an adverse event not reported by [CONTACT_6626], or 
• Local lab r esults document an adverse event severity is worse than the one reported by [CONTACT_30812], or  
• There are no concomitant central results available 
At any time during the study, abnormal laboratory parameters which are clinically relevant,  whether specifically requested in the protocol or not, will be recorded on the AE eCRF 
page. Laboratory data will be summarized using the Common Terminology Criteria for Adverse Events (CTCAE) version 5 ( Section  16.1) . Additional analyses are left to the discretion of the 
investigator.  
[COMPANY_001] must be provided with a copy of the local laboratory’s certification (if applicable), and a tabulation of the normal ranges and units of each parameter collected in the eCRF. Any changes regarding normal ranges and units for laboratory values assessed during the study must be reported via an updated tabulation indicating the date of revalidation.  
The investigator is responsible for reviewing all laborato ry reports for participants in the study 
and evaluating any abnormalities for clinical significance.  
Table 8-[ADDRESS_30192] Name  
[CONTACT_6675], Hemoglobin, Mean Corpuscular Hemoglobin (MCH),  Platelets, Red 
blood cells, White blood cells,  Differential (Basophils, Eosinophils, Lymphocytes, 
Monocytes, Neutrophils, Bands)  
Chemistry  Albumin, Alkaline phosphatase, Alanine Aminotransferase (ALT) , Aspartate 
Aminotransferase (AST) , Gamma -glutamyl transferase (GGT), Lact ate 
dehydrogenase (LDH), Bicarbonate, Calcium, Magnesium, Phosphate (inorganic phosphorus), Chloride, Sodium, Potassium, Creatinine, Creatine kinase (CK), 
Direct Bilirubin, Total Bilirubin, Blood Urea Nitrogen (BUN) or Urea, Uric Acid, 
Amylase, Lipase, Glu cose (non -fasting)  
Urinalysis  Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)  
If needed,  Microscopic Panel (Red Blood Cells, White Blood Cells, Casts, 
Crystals, Bacteria, Epi[INVESTIGATOR_1663])  
[COMPANY_001]  Confidential  Page 68 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Test Category  Test Name  
[CONTACT_30835] 
8.4.2 Electrocardiogram (ECG)  
A standard [ADDRESS_30193] be made by a qualified physician and documented on the appropriate eCRF. ECG tracing should be labeled with the study number, participant initials (where regulations permit), participant number, date and time, and kept in the source documents at the study site.  
Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at any time during the study as clinically indicated. Unscheduled ECGs with clinically significant findings should be collected in triplicate.  
8.4.3 Pregnancy and contraception 
Contraception measures are not required. However, due to potential radiation exposure/contamination to partners, it is recommended that study patients refrain from sexual activity/intercourse for [ADDRESS_30194] for this indication/participant population.  
8.5 Additional assessments 
No additional tests will be performed on participants entered into this study.  
8.5.1 Other Assessments  
Patient Management questionnaire will be completed by [CONTACT_1963]/ Clinical Study Investigator before and within 14 days after having the results of the [
18F]CTT1057 
PET imaging assessmen t by [CONTACT_30813]/CT scans. For subjects assigned to sequence 1, questionnaire 2 should be completed before [
68Ga]Ga -PSMA -11 PET/CT is performed. Refer 
to Section  16.4 for details.  
[COMPANY_001]  Confidential  Page 69 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 [ADDRESS_30195] discontinue study treatment for a given participant if, he/she believes that continuation w ould negatively impact the participant's well -being. 
Discontinuation from Study treatment is required under the following circumstances:  
• Participant non -compliance or voluntary withdrawal from study or from study 
treatment/guardian decision  
• Unacceptable to xicity, as assessed by [CONTACT_737], after the first administration of 
imaging agent that precludes the safe administration of the second imaging agent 
• Any laboratory abnormalities that in the judgment of the Investigator, taking into consideration the participant's overall status, prevents the participant from continuing participation in the study  
• Any other situation in which continued study participation might result in a safety risk to the participant 
• At the Sponsor's or Investigator's discretion. 
For study participants for whom it is required to discontinue from study treatment due to 
unacceptable toxicity resulting in a SAE, refer to Section  10.1.3 for the reporting requirements.  
If discontinuation from study treatment occurs, the investigator should make a reasonable effort to understand the primar y reason for the participant’s discontinuation of study treatment and 
record this information in the source documents and relevant eCRF  pages.  
Participants who discontinue from study treatment can agree to return for the end of treatment and follow -up visits and any efficacy assessment as indicated in the Assessment 
Schedule ( Table 8 -1). 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635], or with a person pre -designated by [CONTACT_2416]. This telephone contact [CONTACT_6636].  
After discontinuation from study treatment, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events 
The investigator must also contact [CONTACT_6637]’s discontinuation from study treatment. 
[COMPANY_001]  Confidential  Page 70 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 9.1.2  Discontinuation from study  
Discontinuation from study is when the participant permanently stops receiving the study 
treatment, and further protocol- required assessments or follow -up, for any reason. If the 
participant agrees, a final evaluation at the time of the participant’s study  discontinuation should 
be made as detailed in the assessment table (refer to Section  8 ). 
9.1.[ADDRESS_30196] to follow -up 
For participants whose status is unclear because they fail to appear for study visits  without 
stating an intention to discontinue from study treatment or discontinue from study or withdraw consent/oppose their use of data or biological samples, the investigator must show "due 
diligence" by [CONTACT_6638], e.g. 
dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -up until due diligence has been completed. 
9.2 Withdrawal of informed consent/Opposition to use 
data/biological samples  
Participants may voluntarily withdraw consent to participate in the study for any reason at any 
time. Withdrawal of consent/opposition to use data/biological samples occurs when a 
participant:  
• Explicitly requests to stop use of their biological samples and/ or data (opposition to use 
participant’s data and biological samples)  
• andNo longer wishes to receive study treatment  
and 
• Does not want to participate in the study anymore, 
and 
• Does not want any further visits or assessments  
and 
• Does not want any further study related contacts 
 
This request should be in writing (depending on local regulations) and recorded in the source 
documentation. 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw his 
consent/opposition to use data/biological samples and record this information.  
Where consent to the use of personal and coded data is not required in a certain country's legal framework, the  participant therefore cannot withdraw consent. However, they still retain the 
right to object to the further collection or use of their personal data.  
Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.  
[COMPANY_001]  Confidential  Page 71 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Further attempts to contact [CONTACT_30814] -up. 
All efforts should be made to complete the assessments prior to study discontinuation. If the participant agrees, a final evaluation at the time of the participant’s withdrawal of consent/opposition to use data/biological samples should be made as detailed in the assessment table.  
[COMPANY_001]  will continue to retain and use all re search results (data) that have already been 
collected for the study evaluation including processing of biological samples that has already started at time of consent withdrawal/opposition. No new Personal Data (including biological samples) will be collected following withdrawal of consent/opposition to use data/biological samples.  
 
9.3 Early study termination by [CONTACT_30815].  
Reasons for early termination:  
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study  
• Discontinuation of study compound (i.e. the investigational imaging agent) development. 
In taking the decision to terminate, [COMPANY_001]  will always consider participant welfare and safety. 
Should early termination be nec essary, participants must be seen as soon as possible  and treated 
as a participant who discontinued from study treatment (e.g.  safety follow up period must be 
completed if applicable with required  visits to be performed ). The investigator may be informed 
of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.   
9.[ADDRESS_30197] visit for the study or, in the event of an early study termination decision, the date of that decision. 
All randomized and/or treated participants will have a Safety Follow up visit at Day 29. The 
information collected is kept as source documentation. All SAEs reported during this time period must be reported as described in Section  10.1.3. Please refer to Table 8 -1 for the required 
assessments at this visit.   
Additional follow up period will be applicable where SoC additional diagnostic procedures are to be performed. These may include SoC pathology, imaging or other modality disease assessments (CTS  Levels 1 or 2)  up to 8 weeks after [
18F]CTT1057 PET imaging, or three -
month follow -up imaging (from baseline)  if clinically required for the diagnosis of particular 
lesion(s).  
[COMPANY_001]  Confidential  Page 72 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 In addition, for participants at CTS Level 3 (i.e. in case CTS  Levels 1 or 2 are not feasible or 
conclusive), PSA levels to be assessed prior to starting RT and at approx. [ADDRESS_30198] -treatment follow -up assessments are completed 
and can be done via a phone call. 
10 Safety monitoring and reporting  
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical 
investigation participant after providing written informed consent for participatio n in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying adverse ev ents. 
[COMPANY_001]  qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the participant 
at each visit during the study. A dverse events also may be detected when they are volunteered 
by [CONTACT_6643], laboratory test findings, or other assessments   
Adverse events must be recorded under the signs, symptoms, or  diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The Common Toxicity Criteria (CTC) AE grad e version  5.0. Grade 1 to 5 will be used to 
characterize the severity of the Adverse Event. Information about any deaths (related to an Adverse Event or not) will also be collected through a Death form 
2. Its relationship to the study investigational imaging agent [
18F]CTT1057, or the imaging 
agent [68Ga]Ga -PSMA -11. If the event is due to progression of underlying illness (i.e. 
exacerbation of pre- existing conditions) the assessment of causality will usually be ‘Not 
suspected.’  The rationale for this guidance is that the symptoms of progression of 
underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_30753], not on a single parti cipant  
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported  
4. Whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
[COMPANY_001]  Confidential  Page 73 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 5. Action taken regarding the study treatment (i.e. discontinuation from the study treatment )  
6. Its outcome. 
If the event worsens the event should be report ed a second time in the CRF noting the start date 
when the event worsens in toxicity. For grade 3 and 4 adverse events only, if improvement to a 
lower grade is determined a new entry for this event should be reported in the CRF noting the start date when t he event improved from having been Grade 3 or Grade 4. 
Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be  described using a 
diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_30199] b e followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the inte rventions required to treat it, and the outcome. 
Information about adverse drug reactions for the investigational drug can be found in the IB. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the fol lowing criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_6533]. 
10.1.2 Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH E15D (2004) Guidelines ). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
[COMPANY_001]  Confidential  Page 74 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_6534]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_30754] e other outcomes listed above. Such events should be 
considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_6536]  (please refer to the 
ICH E15D (2004) Guidelines ). 
All new malignant neoplasms will be assessed as serious under “medically significant ” if other 
seriousness criteria are not met  and the malignant neoplasm is not a disease progression of the 
study indication. 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse of the product are also considered serious adverse event irrespective if a clinical event has occurred.  
10.1.[ADDRESS_30200] be reported to [COMPANY_001]  safety immediately, without undue delay, under no 
circumstances later than within 24 hours of learning of its occurrence. Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each si te. Information about all SAEs is collected and recorded on the electronic 
Serious Adverse Event ( eSAE ) eCRFs (with paper Serious Adverse Event Report Form back -
up); all applicable sections of the eCRFs/form must be completed in order to provide a clinical ly 
thorough report. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_30755] 24 hours of the investigator receiving the follow- up information. An SAE occurring at a 
[COMPANY_001]  Confidential  Page 75 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 different time interval or otherwise considered completely unrelated to a previously reported 
one must be reported separately as a new event.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is thought to be related to the study treatment, a Chief Medical Office and Patient Safety (CMO&PS) Department associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001]  may need to  issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/[ADDRESS_30201] dose of study treatment  should only  
be reported to [COMPANY_001]  Safety if the investigator suspects a causal relationship to study 
treatment.  
10.1.4 Pregnancy reporting  
Not applicable 
10.1.5 Reporting of study treatment errors including misuse 
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency (EMA) definition). 
Misuse refers to situations where the medicinal product/study tr eatment is intentionally and 
inappropriately used not in accordance with the protocol. Study treatment errors and uses outside of what is foreseen in the protocol will be reported 
irrespective of whether or not associated with an AE/SAE (please refer to Table 10-1 for 
guidance on recording on the appropriate CRF) and reported to Safety only if associated with 
an SAE. Misuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE  immediately, without undue delay, under no circumstances later 
than within 24 hours of Investigator’s awareness. 
Table 10-1 Guidance for capturing the study treatment errors including misuse 
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse  Yes Yes, even if not 
associated with an AE  Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the respective sections.  
[COMPANY_001]  Confidential  Page 76 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 10.2 Additional Safety Monitoring  
10.2.1 Steering Committee  
The Steering Committee (SC) will be established comprising investigators  participating in the 
trial and [COMPANY_001]  representatives from the Clinical Trial Team.  
The SC will ensure transparent management of the study according to the protocol through 
recommending and approving modifications as circumstances require. The SC will revi ew 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also develop recommendations for publications of study results including authorship rules. The details of the role of the steering committee will be defined in the st eering committee charter.  
11 Data Collection and Database management  
11.1 Data collection  
Designated investigator staff will enter the data required by [CONTACT_5374] (eCRF). The eCRFs have been built using fully validated secure web -
enabled software that conforms to 21 Code of Federal Regulations (CFR) Part [ADDRESS_30202] been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered into eCRF) is complete, accurate, and that ent ry and updates are performed in a timely manner. 
The Investigator must certify that the data entered are complete and accurate.  
After final database lock, the investigator will receive copi[INVESTIGATOR_6540].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.  
11.2 Database management and quality control  
[COMPANY_001]  personnel (or designated CRO) will review the data entered by [CONTACT_30816] l staff 
for completeness and accuracy. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical conditions and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed to the participant will be 
[COMPANY_001]  Confidential  Page 77 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 tracked using an IRT. The system will be supplied by a vendor, who will also manage the 
database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific 
timelines.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked. Any changes to the database after that time can only 
be made after written agreement by [CONTACT_6652]. 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001]  representative will review the protocol and data capture requirements (i.e. eCRFs) 
with the investigators and their staff. During the study, [COMPANY_001]  employs several methods of 
ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of participant records, the accuracy of data 
capture / data entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each participant in the study, consisting 
of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the participant's file. The investi gator must also keep the original informed consent form signed by 
[CONTACT_2299] (a signed copy is given to the participant). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001]  monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
[ADDRESS_30203] in the stu dy. 
Any data analysis carried out independently by [CONTACT_30817]. 
12.1 Analysis sets  
The Full Analysis Set (FAS)  includes all randomized participants.  
[COMPANY_001]  Confidential  Page 78 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 The Efficacy Analysis Set  (EFF)  includes all randomized participants who receive 
the dose of investigational treatment (i.e. [18F]CTT1057) and have both an evaluable 
[18F]CTT1057 PET/CT scan imaging,  and at least one evaluable CTS assessment and have not 
received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and 
CTS procedures. 
The [18F]CTT1057  Safety Set (F -SAF)  includes all participants who received the 
investigational treatment (i.e. [18F]CTT1057). 
The [68Ga]Ga -PSMA -11 Safety Set (Ga -SAF)  includes all participants who 
received  [68Ga]Ga -PSMA -11. Participants will be analyzed according to the study treatment 
received.  
12.[ADDRESS_30204] deviation, median, minimum, and maximum will be presented. For selected parameter s, 25th and 75th percentiles will also be presented. 
Relevant medical histories and current medical conditions at baseline will be summarized  by [CONTACT_30818]. 
12.3 Treatments  
Actual received dose of [18F]CTT1057 and [68Ga]Ga -PSMA -[ADDRESS_30205] deviation, median, 25th and 75th percen tiles, minimum, and maximum will be 
presented.  
Concomitant medications and significant non- drug therapi[INVESTIGATOR_30756] (ATC) classificatio n system for the FAS.  
12.4 Analysis of the primary endpoint(s)/estimand(s)  
The primary objective of the study is described in Table 2 -1. 
Efficacy analysis will use EFF  
12.4.1 Definition of primary endpoint (s)/estimand(s)  
The co -primary endpoints of the study are region-level CLR and patient- level PPV  
• Region-level CLR is defined as the proportion of regions containing at least one TP lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co -existent FP findings within the same region, out of all regions 
containing at least one PET- positive finding.  
[COMPANY_001]  Confidential  Page 79 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • Patient -level PPV is defined as the proportion of patients who have at least one TP lesion 
(exactly loc alized correspondence between PET imaging and the reference standard), 
regardless of any co -existent FP findings, out of all patients who are PET/CT  scan 
positive.  
Centralized imaging assessments (CTS  Level 2) will be used as reference standard if pathology 
(CTS  Level 1) is not available for a lesion, inconclusive or negative (for biopsy only).  
12.4.2 Statistical model, hypothesis, and method of analysis 
To address the co -primary efficacy objectives:  
Region- l e v e l  C L R  a n d  i t s  9 5 %  C I   will be calculated using logistic random -effects models 
taking into account the correlation among regions within one patient. .The lower bound of the 
95% CI for  CLR should be greater than 0.[ADDRESS_30206] co -primary endpoint.  
Patient -level PPV and its 95% CI  will be calculated ba sed on the binomial distribution. The 
lower bound of the 95% CI for  patient -level  PPV should be greater than 0.2 to attain the second 
co-primary endpoint.  
12.4.3 Handling of remaining intercurrent events of primary estimand 
The primary analyses will account for i ntercurrent events as explained in the following: 
Patients receive the investigational imaging agent [18F]CTT1057 but do not undergo/complete 
the PET/CT scan for any reasons: they will not be used for the co -primary endpoint analyses, 
but safety data will be collected as planned after the administration of the investigational imaging agent. 
12.4.4 Handling of missing values not related to intercurrent event  
This is a diagnostic study, co- primary endpoints are calculated on the basis of one -time imaging 
assessment,  missing data not related to intercurrent events will not be imputed.  
12.4.5 Sensitivity analyses for primary endpoint/estimand 
The lower level of CTS will be used to verify positivity or negativity for the sensitivity analysis. 
For instance, if pathology (CTS  Level 1) is used as true standard for primary estimand, imaging 
component of CTS (Level 2) will be used as true standard for sensitivity analysis for primary estimand. However, for those using changes in PSA level (CTS  Level 3) as the true standard 
for prima ry estimand, their positivity status cannot be replaced by [CONTACT_30819]. 
12.4.6 Supplementary analysis 
As supplementary analyses performed in the EFF, the region -level CLR  and patient -level PPV 
and 95% CIs will be obtained fro m covariate adjusted logistic regression model. Important 
covariate will be specified in the SAP.   
Subgroup analyses for region- level CLR  and patient- level PPV will be performed:  
• patients with prior radical prostatectomy  
[COMPANY_001]  Confidential  Page 80 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • patients  with prior curative inten t radiation therapy  
If the co -primary endpoints are met, other subgroup analyses to assess the homogeneity of the 
treatment effect across demographic and baseline disease characteristics will be performed. 
Other subgroups will be specified in the SAP. Furt her supplementary analyses will be specified 
in the SAP.   
12.5 Analysis of secondary endpoints/estimands  
The secondary objectives and related endpoints are described in Table 2 -1. 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
Following secondary endpoints, centralized imaging assessment will be used as reference standard if pathology assessment is not available for a lesion.  
Patient -level sensitivity  is defined as the proportion of TP  patients among those who are TP or 
FN 
Patient -level specificity  is defined as the proportion of TN  patients among those who are TN 
or FP 
Patient -level negative predictive value  is defined as the proportion of TN  patients among 
those who are TN or FN   
Patient -level accuracy  is defined as the proportion of TP and TN patients among all scanned 
patients (regardless of TP, TN, FP, FN)  
Patient -level correct detection rate is defined as the proportion of TP patients among all 
scanned patients (regardless of T P, TN, FP, FN)  
Patient -level detection rate  is defined as the proportion of TP and FP patients among all 
scanned patients (regardless of TP, TN, FP, FN) where  TP, TN, FP, FN patients are defined as follows:   
• PSMA TP patients are those who have at least one TP lesion with anatomically localized 
correspondence between [
18F]CTT1057 PET imaging and the CTS. 
• PSMA TN patients are those who  do not show any pathological [18F]CTT1057 uptake and 
will be confirmed NOT  having any lesions with the CTS. 
• PSMA FP patients are those who  show at least one pathological [18F]CTT1057 uptake but 
will be verified NOT having any lesions with the CTS or none is correctly localized in anatomical location by [CONTACT_30820]. 
• PSMA FN patients are those who  do not show any pathological [
18F]CTT1057 uptake but 
will be confirmed having  at least one with the CTS.  
Number of TP, TN, FP, FN patients will be presented and used to calculate the diagnostic performance parameters.   
95% CI for  diagnostic performance parameters  will be calculated based on t he binomial 
distribution. 
[COMPANY_001]  Confidential  Page 81 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 [18F]CTT1057 scan inter -reader variability  is defined as agreement among three readers 
determinations and will be assessed by [CONTACT_30821]' Kappa statistic. Details of calculation of Fleiss' 
Kappa statistic in SAP.  
[18F]CTT1057 scan int ra-reader variability  is defined as  within -reader agreement for two 
different time points and will be assessed by [CONTACT_30822]'s Kappa statistic. A subset of imaging reading will be performed at two different time points by [CONTACT_30783]. See details in imaging charter. Details of calculation of Cohen's Kappa statistic in SAP. 
Change in patient management plans  attributed to the [
18F]CTT1057  PET/CT scan  is defined 
as the percentage of patients who undergo a change in intended treatment plan attributed to the PET/CT scan as assessed by [CONTACT_30823] [ADDRESS_30207] imaging questionnaire 2  
Numbers and percentage of patients on each category of treatment plan:   surgery, radiation 
alone, radiation alone with change in radiation treatment plan (only applicable for questionnaire 
2), radiation plus ADT, ADT alone, observation/surveillance, other (free text box) in two 
questionnaires will be calculated.  
Treatment plan change is defined as a pair of categories (one category of questionnaire 1, one category of questionnaire 2)  
Numbers and percentage of patients on the treatment change defined above will be calculated.  
The following secondary endpoints, centralized imaging assessment will be used as reference standard if pathology assessment is not available for a lesion . 
Region- level sensitivity  is defined as the proportion of TP regions among those that are TP or 
FN 
Region- level specificity  is defined as the proportion of TN regions among those that are TN or 
FP 
Region- level negative predictive value is defined as the p roportion of TN regions among those 
that are TN or FN  
Region- level accuracy  is defined as the proportion of TP  and TN regions among those that are 
identified on [
18F]CTT1057 (regardless of TP, TN, FP, FN)  
where  TP, TN, FP, FN regions are defined as follows: 
• PSMA TP regions are regions containing at least one TP lesion (anatomically localized 
correspondence between [18F]CTT1057 PET imaging and the CTS).  
• PSMA TN regions are regions containing no lesions with pathological [18F]CTT1057 
uptake and confirmed by [CONTACT_30824].  
• PSMA FP regions are  regions containing lesions with pathological [18F]CTT1057 uptake 
but will be verified negative by [CONTACT_30825].  
• PSMA FN regions are regions containing no lesions with  pathological [
18F]CTT1057 
uptake but will be confirmed having at least one lesions with the CTS.  
Number of TP, TN, FP, FN regions will be presented and used to calculate the diagnostic performance parameters.   
[COMPANY_001]  Confidential  Page 82 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 95% CI for region -level diagnostic perfor mance parameters  will be calculated using logistic 
random- effects models taking into account the correlation among regions within one patient.   
For different regions ( i.e.  prostate region, PLN, extra -PLN, skeletal, visceral), 95% CI for 
region- level diagnostic performance parameters will be calculated  based on the binomial 
distribution respectively.  
Patient -level positive predictive value will be also calculated for different categorical PSA 
levels.  
Concordance between [18F]CTT1057 and [68Ga]Ga -PSMA -11 for detection of lesions, 
positive percent agreement will be calculated to assess the concordance.  
12.5.2 Safety endpoints 
Safety summaries (tables, figures) include only data from the on -treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary for death including on treatment and post treatment deaths will be provided. In particular, summary tables for adverse events (AEs) will summarize only on- treatment events, with a start date during the on -treatment period 
(treatment -emergent AEs). [
18F]CTT1057 treatment- emergent AEs, [68Ga]Ga -PSMA -11 
treatment- emergent AEs will be presented using F -SAF and Ga -SAF separately.   
The overall observati on period will be divided into three mutually exclusive segments:  
1. Pre-treatment period: from day of participant’s informed consent to the day and time 
before dosing of study treatment 
2. On-treatment period: from day of dosing of study medication to  approximately [ADDRESS_30208]-treatment period: starting at day  15 after dosing of study medication. 
Adverse events 
All information obtained on adverse events will be displayed by [CONTACT_3445].  
The number (and percentage) of participants with treatment emergent adverse events (events 
started after the first dose of study medication or events present prior to start of study treatment but increased in severity based on preferred term) will be summarized in the following ways: 
• primary syste m organ class and preferred term.  
• primary system organ class, preferred term and maximum severity. 
• Standardized MedDRA Query (SMQ) and preferred term.  
Separate summaries will be provided for study medication related adverse events, death, serious 
adverse events, other significant adverse events leading to drug interruption, and adverse events leading to drug withdrawn. 
A participant with multiple adverse events within a primary system organ class is only counted 
once towards the total of the primary system organ class.  
[COMPANY_001]  Confidential  Page 83 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Summary tables for adverse events (AEs) will include only AEs that started or worsened during 
the on- treatment period, the  treatment -emergent  AEs.  
The incidence of treatment -emergent adverse events (new or worsening from baseline) will be 
summ arized by [CONTACT_30826], severity (based on CTCAE grades), 
type of adverse event, relation to study treatment.  
Serious adverse events, non -serious adverse events during the on- treatment period will be 
tabulated. 
All deaths (on -treatment and post- treatment) will be summarized.  
All AEs, deaths, and serious adverse events (including those from the pre and post -treatment 
periods) will be listed and those collected during the pre -treatment and post -treatment period 
will be flagged.  
Vital signs  
All vital signs data will be listed by [CONTACT_3445], and visit/time and clinically notable values or 
changes in vital signs will be flagged. Summary statistics will be provided by [CONTACT_765]/time.  
12-lead ECG  
All ECG data will be listed by [CONTACT_30827]/time, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_765]/time.   
Clinical laboratory evaluations 
All laboratory data will be listed by  [CONTACT_30827]/time and if normal ranges are available 
abnormalities will be flagged. Summary statistics will be provided by [CONTACT_765]/time. Shift tables 
using the low/normal/high/ (low and high)  classification will be used to compare baseline to the 
worst on- treatment value.  
Grading of laboratory values will be assigned programmatical ly as per National Cancer Institute 
(NCI) CTCAE version 5.0 . The calculation of CTCAE grades will be based on the observed 
laboratory values only, clinical assessments will not be taken into account.  
CTCAE Grade 0 will be assigned for all non- missing values not graded as 1 or higher. Grade 5 
will not be used.  
For laboratory tests where grades are not defined by [CONTACT_30828] 5.0, results will be categorized as low/normal/high based on laboratory normal ranges. 
The following listings/summaries will be generated separately for hematology, and 
biochemistry tests:  
• Listing of all laboratory data with values flagged to show the corresponding CTCAE version 5.0 grades if applicable and the classifications relative to the laboratory normal ranges 
For laboratory tests where grades are defined by [CONTACT_30828]  5.0: 
[COMPANY_001]  Confidential  Page 84 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 • Worst post- baseline CTCAE grade (regardless of the baseline status). Each participant 
will be counted only once for the worst grade observed post- baseline.  
• Shift tables using CTCAE version 5.[ADDRESS_30209] on-
treatment value  
For laboratory tests where grades are not defined by [CONTACT_30828] 5.0: 
• Shift tables using the low/normal/high/ (low and high) classification to compare baseline 
to the worst on- treatment value.  
In addition to the above mentioned tables and listings, other , for example, 
figures plotting time course of raw or change in laboratory tests over time or box plots might 
be specified in the analysis plan.  
12.[ADDRESS_30210] 152 participants are 
evaluable (i.e. have both an evaluable [18F]CTT1057 PET/CT scan imaging,  and at least one 
evaluable CTS assessment and have not received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and CTS procedures), which will be required for the 

[COMPANY_001]  Confidential  Page 85 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 calculation of the co -primary endpoints . These calculations were made using the software PASS 
11 and R 3.6.1. 
12.8.1 Primary endpoint(s)  
This study is planned to recruit approximately 190 patients. The sample size calculation is based 
on the co-primary endpoints of region- level CLR  and the patient-level PPV of [18F]CTT1057. 
The assumptions for sample size calculations are based on t he estimates from data available 
from prior studies.  
The primary endpoint is to evaluate region- level CLR (prostate region, PLN, extra -PLN, 
skeletal, visceral) and patient- level PPV of [18F]CTT1057 PET for detection of tumor location 
confirmed by [CONTACT_26745]/biopsy. Based on the results of previous studies, the following distribution of disease across regions are anticipated: Prostate bed: 30%, pelvis: 15%; extrapelvic soft tissue: 20%; bone metastases: 35% ( Eiber  et al 2015, Ceci et al 2015, 
Van Leeuwen  et al 2016 ). It is anticipated that the CLR for the five regions and for all regions 
combined using conventional imaging ranges from 30- 60%. An overall CLR for [
18F]CTT1057 
PET of at most 50% will be considered as unacceptably low.  Hence, the null hypothesis that 
the CLR is at most 50% will be tested against the alternative hypothesis that the CLR is greater than 50%.  
The BCR population targeted in this study is expected to have similar  PSA values than prior 
studies ( Morris  et al 2020) of approved diagnostic PET agents for PCa such as [
18F]-
fluciclovine, which had a 27% PPV for patients with PSA values that were less than 1.78, as noted in their summary basis of approval. Thus, a patient -level PPV of 20% will be considered 
as unacceptably low. The [
18F]CTT1057 positive patient rate (detection rate) for the study 
population is 80% based on [18F]-fluciclovine studies. The sample size calculation will be 
performed based on the null and alternative hypotheses as follows. 
• Region- level CLR:  
Correlated binary test results occur in this situation where each experimental unit (patient) 
consists of five correlated regions. Lee and Dubin developed a sample size formula for clu stered 
binary data ( Lee and Dubin 1994).  They propose estimating the binary proportion by [CONTACT_30829]. The weighted estimator for region -level CLR is approximately Gaussian distributed 
with a variance of a beta distribution (beta- binomial model).   
The null Hypothesis H0: region -level CLR p = 0.[ADDRESS_30211] the alternative  
hypothesis H1: p >0.5  Assuming a CLR of 0.58 under the alternative hypothesis, a total sample 
size of 172 enrolled participants would achieve 90% statistical power to detect a change in CLR of 0.[ADDRESS_30212] at a target significance level of 2.5%.This sample size includes 
an adjustment for a dropout rate of 0.20.  
To determine the sample size n such that the type I error of one -sided testing H0 is 0.[ADDRESS_30213] normal approxim ation, the 
sample size is given  
[COMPANY_001]  Confidential  Page 86 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 
 
where σ2 the variance of a beta distribution, Z a is the upper a quantile of the standard normal 
distribution, p [ADDRESS_30214] results. In this case, a 
uniform distribution seems reasonable, setting parameters in the beta distribution alpha=1 and 
beta=1. Then σ2 is 1/12 
Under these assumptions, 137 patients will be necessary to ensure the 90% powe r, taking into 
account 20% dropout rate, a total of 172 patients will be recruited for this endpoint of the study.  
The lower bound of the 95% CI for CRL should be greater than 0.5 to be considered success.  
• Patient -level PPV  
The null Hypothesis H0: patient -level PPV p = 0.[ADDRESS_30215] the alternative 
hypothesis H1: p >0.2  Assuming a patient -level PPV of 0.33 under the alternative hypothesis, 
a total sample size of 190 enrolled participants (which includes 152 [18F]CTT1057 scanned 
patients based on 80% [18F]CTT1057 positive patient rate) would achieve 90% statistical power 
to detect a change in patient -level PPV of 0.[ADDRESS_30216] at a target 
significance level of 2.5%.This sample size includes an adjustment for a dropout rate of 20%. 
The lower bound of the 95% CI for patient -level PPV should be greater than 0.2 to be considered 
success.  
A total sample size of 190 patients can ensure 92.7% statistical power for region- level CLR and 
90% statistical power for patient- level PPV resulting in an overall study statistical power of at 
least 83.4% (0.927*0.9).  
13 Ethical considerations and administrative procedures  
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for GCP, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki.  
13.2 Responsibilities of the inve stigator and IRB/IEC  
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent fo rm updates, participant recruitment procedures (e.g., 
advertisements) and any other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001]  Quality Assurance representatives, designated agents of [COMPANY_001], 
[COMPANY_001]  Confidential  Page 87 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform [COMPANY_001]  immediately that this 
request has been made.  
13.[ADDRESS_30217]. In addition, after study completion and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT etc.). 
For details on the [COMPANY_001]  publi cation policy including authorship criteria, please refer to the 
[COMPANY_001]  publication policy training materials that were provided to you at the trial investigator 
meetings.  
13.[ADDRESS_30218] Quality Manageme nt System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001]  systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conduct ed to assess GCP compliance with global and local regulatory requirements, 
protocols and internal Standard Operating Procedures (SOPs), and are performed according to written [COMPANY_001]  processes.  
[ADDRESS_30219] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_30830]/IEC and Health Authorities, where required, it cannot be 
implemented.  
[COMPANY_001]  Confidential  Page 88 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 14.[ADDRESS_30220] be approved by [CONTACT_5343], health authorities w here required, and the IRB/IEC prior to 
implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant  included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
  
[COMPANY_001]  Confidential  Page 89 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 [ADDRESS_30221]  
[68Ga]Ga -PSMA -11 U.S Prescribing Information (USPI) FDA (Internet) Available from: 
accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf (Accessed Dec-2020). 
Afshar -Oromieh A, Avtzi E, Giesel FL, et al (2015) The diagnostic value of PET/CT imaging 
with the (68)Ga -labelled PSMA ligand HBED -CC in the diagnosis of recurrent prostate 
cancer. Eur J Nucl Med Mol Imaging; 42:197-209. Afshar -Oromieh A, Holland-Letz T, Giesel FL, et al (2017) Diagnostic performance of 68Ga-
PSMA -11 (HBED- CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 
patients. Eur J Nucl Med Mol Imaging; 44:1258-68. Afshar -Oromieh A, Malcher A, Eder M, et al (2013) PET imaging with a [68Ga]gallium-
labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first 
evaluation of tumour lesions. Eur J Nucl Med Mol Imaging; 40:486-95. 
Afshar -Oromieh A, Zechmann CM, Malcher A, et al (2014) Comparison of PET imaging with 
a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of 
recurrent prostate cancer. Eur J Nucl Med Mol I maging; 41:11-20. 
Behr S, Aggarwal R, Flavell R, et al (2017) Comparison of a novel fluorine-18 labeled PSMA -targeting agent, CTT1057, to gallium- 68 PSMA -11 in patients with prostate cancer 
[abstract]. J Nucl Med; [ADDRESS_30222] 1:733A. 
Behr SC, Aggarwal R, VanBrocklin HF, et al (2019) Phase I Study of CTT1057, an 18F-
Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate- Specific Membrane 
Antigen in Prostate Cancer. J Nucl Med; 60(7):910-6. 
Blomqvist L, Carlsson S, Gjertsson P, et al (2014) Limited e vidence for the use of imaging to 
detect prostate cancer: a systematic review. Eur J Radiol; 83:[ADDRESS_30223] R, Delgado-Bolton R, Oyen WJG, et al (2015) FDG PET/CT: EANM procedure 
guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging; 42:328- 54. 
Bostwick DG, Pacelli A, Blute M, et al (1998) Prostate specific membrane antigen expression in prostatic intraepi[INVESTIGATOR_30758]: a study of 184 cases. Cancer; 82(11):2256-61. 
Bott SRJ (2004) Management of recurrent disease  after radical prostatectomy. Prostate Cancer 
and Prostatic Dis; 7:211-6. Bravaccini S, Puccetti M, Bocchini M, et al (2018) PSMA expression: a potential ally for the 
pathologist in prostate cancer diagnosis. Sci Rep; 8:4254. 
Bray F, Ren JS, Masuyer E, et al (2013) Global estimates of cancer prevalence for 27 sites in 
the adult population in 2008. Int J Cancer; 132:1133-45. 
[COMPANY_001]  Confidential  Page 90 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Budäus L, Leyh-Bannurah SR, Salomon G, et al (2016) Initial Experience of (68)Ga- PSMA 
PET/CT Imaging in High -risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur 
Urol; 69:393-6. 
Calais J, Kishan AU, Cao M, et al (2018) Potential Impact of 68Ga- PSMA -11 PET/CT on the 
Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med; 59(11):1714-21. 
Ceci F, Uprimny C, Nilica B, et al (2015) (68)Ga- PSMA PET/CT for restaging recurrent 
prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med 
Mol Imaging; 42:1284-94. 
Chantadisai M, Buschner G, Krönke M, et al (2020) Positive predictive value and correct 
detection rate of 18F- rhPSMA -[ADDRESS_30224]. J Nucl Med; 12:1 -38. 
Conti M, Eriksson L (2016) Physics of pure and non- pure positron emitters for PET: a review 
and a discussion. EJNMMI Physics; 3(1):1-17. 
Cookson MS, Aus G, Burnett AL, et al (2007) Variation in the definition of biochemical 
recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol;177(2):540-5. 
Eiber M, Maurer T, Souvatzoglou M, et al (2015) Evaluation of Hybrid ⁶⁸Ga -PSMA Ligand 
PET/CT in 248 Patients with B iochemical Recurrence After Radical Prostatectomy. J Nucl 
Med; 56(5):668-74. 
Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer; 45:228- 47. 
Fendler WP,  Calais J, Eiber M, et al (2019) Assessment of 
68Ga-PSMA -11 PET Accuracy in 
Localizing Recurrent Prostate Cancer: A Prospective Single -Arm Clinical Trial. JAMA 
Oncol; 5(6):856-63. 
Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) 
and its regulation in prostate cancer. J Cell Biochem; 91:528 -39. 
Haffner MC, Kronberger IE, Ross JS, et al (2009) Prostate- specific membrane antigen 
expression in the neovasculature of gastric and colorectal cancers. Hum Pathol; 40:1754-61. 
Han S, Woo S, Kim YJ, et al (2018) Impact of 68Ga- PSMA PET on the Management of 
Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol; 74:179-90. 
Hope TA, Goodman JZ, Allen IE, et al (2019) Metaanalysis of 68Ga- PSMA -11 PET 
Accuracy for the Detection of Prostate Cancer Validated by [CONTACT_30831]. J Nucl Med; 
60(6):786- 93. 
Hricak H, Dooms GC, Jeffrey RB, et al (1987) Prostatic carcinoma: staging by [CONTACT_13113], CT, and MR imaging. Radiology; 162:331-6. 
[COMPANY_001]  Confidential  Page 91 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Hupe MC, Philippi C, Roth D, et al (2018) Expression of Prostate- Specific Membrane 
Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at 
Time of Initial Diagnosis. Front Oncol; 8:623. 
Hövels AM, Heesakkers RAM, Adang EM, et al (2008) The di agnostic accuracy of CT and 
MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta -analysis. 
Clin Radiol; 63:387-95. 
ICH E2D (2004) Clinical Safety Data Management: Definitions and Standards for expedited 
reporting (Internet) Ava ilable from: 
ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002807.pdf (Accessed 15 January 2021). 
Isbarn H, Wanner M, Salomon G, et al (2010) Long- term data on the survival of patients with 
prostate cancer treated with radical  prostatectomy in the prostate -specific antigen era. BJU Int; 
106:37-43. 
Jani AB (2006) Management strategies for locally advanced prostate cancer. Drugs Aging; 
23(2):119- 29. 
Kaushik A, Jaimini A, Tripathi M, et al (2015) Estimation of radiation dose to pa tients from 
(18) FDG whole body PET/CT investigations using dynamic PET scan protocol. Indian J Med Res; 142:721-31. 
Kuten J, Fahoum I, Savin Z, et al (2020) Head- to-Head Comparison of 68Ga- PSMA -11 with 
18F- PSMA -1007 PET/CT in Staging Prostate Cancer Using Histopathology and 
Immunohistochemical Analysis as a Reference Standard. J Nucl Med; 61(4):527 -32. 
Lee EW, Dubin N (1994) Estimation and sample size considerations for clustered binary 
responses. Stat Med; 13:1241-52. 
Malvezzi M, Carioli G, Bertuccio P, et al (2019) European cancer mortality predictions for 
the year [ADDRESS_30225] cancer. Ann Oncol; 30(5):781-7. 
Morris MJ, Carroll PR, Saperstein L, et al (2020) Impact of PSMA -targeted imaging with 
18F- DCFPyL -PET/CT on clinical management of pati ents (pts) with biochemically recurrent 
(BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study 
(CONDOR) [abstract]. J Clin Oncol; 38 ([ADDRESS_30226]):5501A. 
Nanni C, Zanoni L, Pultrone C, et al (2016) (18)F- FACBC (anti1 -amino -3-(18 )F-
fluorocyclobutane-1-carboxylic acid) versus (11)C- choline PET/CT in prostate cancer relapse: 
results of a prospective trial. Eur J Nucl Med Mol Imaging; 43:1601-10. Odewole OA, Tade FI, Nieh PT, et al (2016) Recurrent prostate cancer detection with anti-3-
[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging; 43:1773-83. 
Oh WK, Kantoff PW (1999) Treatment of locally advanced prostate cancer: is chemotherapy 
the next step? J Clin Oncol; 17(11):3664-75. 
[COMPANY_001]  Confidential  Page 92 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Perera M, Papa N, Christidis D, et al ( 2016) Sensitivity, Specificity, and Predictors of Positive 
68Ga- Prostate -specific Membrane Antigen Positron Emission Tomography in Advanced 
Prostate Cancer: A Systematic Review and Meta- analysis. Eur Urol; 70:926 -37. 
Pernthaler B, Kulnik R, Gstettner C, et al (2019) A Prospective Head- to-Head Comparison of 
18F- Fluciclovine With 68Ga -PSMA -11 in Biochemical Recurrence of Prostate Cancer in 
PET/CT. Clin Nucl Med; 44(10):e566-e73. 
Petersen LJ, Zacho HD (2020) PSMA PET for primary lymph node staging of intermedi ate 
and high- risk prostate cancer: an expedited systematic review. Cancer Imaging; 20:10.  
Prasad V, Steffen IG, Diederichs G, et al (2016) Biodistribution of [(68)Ga]PSMA- HBED- CC 
in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs  and Tumour 
Lesions. Mol Imaging Biol; 18:428- 36. 
Roach M, Hanks G, Thames H, et al (2006) Defining biochemical failure following 
radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG -ASTRO Phoenix Consensus Conference. Int J Radiat 
Oncol Biol Phys;65(4):965-74. 
Roscigno M, Sangalli M, Mazzoccoli B, et al (2005) Medical therapy of prostate cancer. A 
review. Minerva Urol Nefrol; 57(2):71 -84. 
Ross JS, Sheehan CE, Fisher HAG, et al (2003) Correlation of primary tumor prostate -
specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res.; 9:6357-62. 
Scheidler J, Hricak H, Vigneron DB, et al (1999) Prostate cancer: localization with three -
dimensional proton MR spectroscopic imaging-- clinicopathologic study. Radiology; 
213(2):473-80. 
Scher HI, Morris MJ, Stadler WM, et al (2016) Trial Design and Objectives for Castration -
Resistant Prostate Cancer: Updated Recommendations From the Prost ate Cancer Clinical 
Trials Working Group 3. J Clin Oncol; 34(12):1402-18. 
Schmidt LH, Heitkötter B, Schulze AB, et al (2017) Prostate specific membrane antigen 
(PSMA) expression in non-small cell lung cancer. PLoS ONE; 12(10):e0186280. 
Schwarzenböck S, Souvatzoglou M, Krause BJ (2012) Choline PET and PET/CT in Primary 
Diagnosis and Staging of Prostate Cancer. Theranostics; 2(3):318-30. 
Shinohara K, Wheeler TM, Scardino PT (1989) The appearance of prostate cancer on 
transrectal ultrasonography: correlation o f imaging and pathological examinations. J Urol; 
142:76-82. 
Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin; 67(1):7 -30. 
Siegel RL, Miller KD, Jemal A (2018) Cancer Statistics, 2018. CA Cancer J Clin; 68(1):7 -30. 
Siegel RL, M iller KD, Jemal A (2019) Cancer Statistics, 2019. CA Cancer J Clin; 69(1):7 -34. 
[COMPANY_001]  Confidential  Page 93 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Smith RA, Andrews K, Brooks D, et al (2016) Cancer screening in the [LOCATION_002], 2016: A 
review of current American Cancer Society guidelines and current issues in cancer scr eening. 
CA Cancer J Clin; 66(2):95 -114. 
Spatz S, Tolkach Y, Jung K, et al (2018) Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol; 199:370-7. 
Stock K, Steinestel K, Wiesch R, et al (2017) Neovascular Prostate- Specific Membrane 
Antigen Expression Is Associated with Improved Overall Survival under Palliative 
Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Biomed Res Int; 28 [ZIP_CODE]. 
Szabo Z, Mena E, Rowe SP, et al (2015) Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA) -Targeted PET Imaging of Prostate Cancer. Mol 
Imaging Biol; 17(4):565 -74. 
Tanjore Ramanathan J, Lehtipuro S, Sihto H, et al (2020) Prostate -specific membrane antigen 
expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to  the brain. J Cell Mol Med; 24:6916-27. 
Tolkach Y, Gevensleben H, Bundschuh R, et al (2018) Prostate- specific membrane antigen in 
breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat; 169:447-55. 
Tolkach Y, Goltz D, Kremer A, et al (2019) Prostate -specific membrane antigen expression in 
hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget; 
10(41):4149-60. 
Van Leeuwen PJ, Stricker P, Hruby G, et al (2016) (68) Ga- PSMA has a high detection rate of 
prostate cancer recurrence outside the prostatic fossa in patients b eing considered for salvage 
radiation treatment. BJU Int; 117:732 -9. 
Van Poppel H, Vekemans K, Da Pozzo L, et al (2006) Radical prostatectomy for locally 
advanced prostate cancer: results of a feasibility study (EORTC [ZIP_CODE]). Eur J Cancer; 42:1062-7. 
Von Eyben FE, Pi[INVESTIGATOR_30759] M, von Eyben R, et al (2018) 68Ga- Labeled Prostate- specific 
Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for 
Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus; 4:686-93. 
Wang HL, Wang SS, Song WH, et al (2015) Expression of prostate- specific membrane 
antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical 
significance. PLoS ONE; 10(5):e0125924. 
Wernicke AG, Edgar MA, Lavi E, et al (2011) Prostate- specific memb rane antigen as a 
potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab 
Med; 135:1486-9. 
[COMPANY_001]  Confidential  Page 94 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 Wernicke AG, Kim S, Liu H, et al (2017) Prostate- specific Membrane Antigen (PSMA) 
Expression in the Neovasculature of Gynecologic M alignancies: Implications for PSMA -
targeted Therapy. Appl Immunohistochem Mol Morphol; 25(4):271-6. 
Yaxley JW, Dagher J, Delahunt B, et al (2018) Reconsidering the role of pelvic lymph node 
dissection with radical prostatectomy for prostate cancer in an er a of improving radiological 
staging techniques. World J Urol; 36:15-20. 
Yaxley JW, Raveenthiran S, Nouhaud FX, et al (2019a) Risk of metastatic disease on 68 
gallium- prostate -specific membrane antigen positron emission tomography/computed 
tomography scan f or primary staging of 1253 men at the diagnosis of prostate cancer. BJU 
Int; 124:401-7. 
Yaxley JW, Raveenthiran S, Nouhaud FX, et al (2019b) Outcomes of Primary Lymph Node 
Staging of Intermediate and High Risk Prostate Cancer with 68Ga- PSMA Positron Emission 
Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. J Urol; 201:815-20. 
[COMPANY_001]  Confidential  Page 95 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 16 Appendices  
16.1 Appendix 1: Common Terminology Criteria for Adverse Events  
The complete NCI CTCAE (version 5.0) can be found at the following site:  
[ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Refe
rence_8.5x11.pdf]   
[COMPANY_001]  Confidential  Page 96 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 16.2 Appendix 2: Response Evaluation Criteria in Solid Tumors  
The latest RECIST guidelines (version 1.1) can be found at the following site:  
[project.eortc.org/recist/wp -content/uploads/sites/4/2015/03/RECISTGuidelines.pdf]   
[COMPANY_001]  Confidential  Page 97 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 16.3 Appendix 3: PCWG3 
The sections that apply to this trial are the criteria for PSA response and progression, and the 
criteria for bone lesion “prevent/delay e nd points” (progression). It is based on the PCWG3 
recommendations ( Scher  et al 2016).  
[COMPANY_001]  Confidential  Page 98 of 98  
Amended Protocol (Version No. 01 Clean)   Protocol No. CAAA405A12301  
 
 
 16.4 Appendix 4: Patient Management questionnaire 
A questionnaire on the planned patient management wil l be filled -in by [CONTACT_30780]/Clinical Study Investigator before (questionnaire 1) and within 14 days after knowing 
the results of the [18F]CTT1057 PET/CT scan (questionnaire 2). 
Options will be given in the questionnaire to capture possible management plan, such as 
• Surgery 
• Radiation alone  
• Radiation alone with change in radiation treatment plan (only applicable for questionnaire 
2) 
• Radiation plus ADT 
• ADT alone  
• Observation/surveillance  
• Other (free text box) 
The results of the [18F]CTT1057 PET/CT s can will be provided to the Study Investigator before 
the patient undergoes the planned treatment by a local nuclear medicine physician or radiologist with expertise in reading oncology PET/CT scans, who will be blinded to [
68Ga]Ga -PSMA -[ADDRESS_30227] of the investigational procedure.  